US20100260815A1 - Fluid concentrator, autologous concentrated body fluids, and uses thereof - Google Patents
Fluid concentrator, autologous concentrated body fluids, and uses thereof Download PDFInfo
- Publication number
- US20100260815A1 US20100260815A1 US12/666,131 US66613108A US2010260815A1 US 20100260815 A1 US20100260815 A1 US 20100260815A1 US 66613108 A US66613108 A US 66613108A US 2010260815 A1 US2010260815 A1 US 2010260815A1
- Authority
- US
- United States
- Prior art keywords
- fluid
- concentrated
- filter
- concentrator
- biological fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 243
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 70
- 239000010839 body fluid Substances 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 109
- 238000000926 separation method Methods 0.000 claims abstract description 108
- 210000001519 tissue Anatomy 0.000 claims description 90
- 210000004027 cell Anatomy 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 239000000463 material Substances 0.000 claims description 51
- 239000013060 biological fluid Substances 0.000 claims description 50
- 239000003102 growth factor Substances 0.000 claims description 49
- 210000000988 bone and bone Anatomy 0.000 claims description 44
- 210000000130 stem cell Anatomy 0.000 claims description 40
- 238000001914 filtration Methods 0.000 claims description 39
- 230000012010 growth Effects 0.000 claims description 36
- 230000004069 differentiation Effects 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 33
- 208000027418 Wounds and injury Diseases 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 238000005119 centrifugation Methods 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 31
- 210000000845 cartilage Anatomy 0.000 claims description 29
- 239000005482 chemotactic factor Substances 0.000 claims description 29
- 230000035876 healing Effects 0.000 claims description 27
- 239000012528 membrane Substances 0.000 claims description 27
- 239000002121 nanofiber Substances 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 26
- 206010052428 Wound Diseases 0.000 claims description 24
- 210000004379 membrane Anatomy 0.000 claims description 21
- 238000001356 surgical procedure Methods 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 18
- 210000001185 bone marrow Anatomy 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 14
- 230000007547 defect Effects 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 13
- 208000014674 injury Diseases 0.000 claims description 13
- 239000011800 void material Substances 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 12
- 239000011521 glass Substances 0.000 claims description 12
- 210000004872 soft tissue Anatomy 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 238000004891 communication Methods 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- 239000004033 plastic Substances 0.000 claims description 9
- 229920003023 plastic Polymers 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 claims description 9
- 239000003894 surgical glue Substances 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 239000010703 silicon Substances 0.000 claims description 8
- 229910052710 silicon Inorganic materials 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 229920001410 Microfiber Polymers 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 239000003658 microfiber Substances 0.000 claims description 7
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 6
- 230000003416 augmentation Effects 0.000 claims description 6
- 210000002805 bone matrix Anatomy 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 208000002847 Surgical Wound Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000003041 ligament Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 208000017234 Bone cyst Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 238000005299 abrasion Methods 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 206010033675 panniculitis Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 208000035874 Excoriation Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims description 2
- 238000000149 argon plasma sintering Methods 0.000 claims description 2
- 208000028528 solitary bone cyst Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 description 106
- 210000004623 platelet-rich plasma Anatomy 0.000 description 66
- 239000000306 component Substances 0.000 description 51
- 238000002955 isolation Methods 0.000 description 24
- 241000283690 Bos taurus Species 0.000 description 22
- 239000002243 precursor Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000012546 transfer Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- -1 FGFb Proteins 0.000 description 12
- 230000000975 bioactive effect Effects 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 8
- 230000023597 hemostasis Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 102000007072 Nerve Growth Factors Human genes 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000005484 gravity Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000021559 Dicerandra Species 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 235000010654 Melissa officinalis Nutrition 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000008468 bone growth Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000000865 liniment Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 4
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 4
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- 101710142969 Somatoliberin Proteins 0.000 description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 4
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 4
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 4
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 4
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 4
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000399 orthopedic effect Effects 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000565 sealant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010059712 Pronase Proteins 0.000 description 3
- 102000005157 Somatostatin Human genes 0.000 description 3
- 108010056088 Somatostatin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- 239000003106 tissue adhesive Substances 0.000 description 3
- 229940075469 tissue adhesives Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 2
- 108010068307 Alpha-Globulins Proteins 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 102000006734 Beta-Globulins Human genes 0.000 description 2
- 108010087504 Beta-Globulins Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000006433 Chemokine CCL22 Human genes 0.000 description 2
- 108010083701 Chemokine CCL22 Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 102000012192 Cystatin C Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102100029290 Transthyretin Human genes 0.000 description 2
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 2
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 210000004395 cytoplasmic granule Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000002321 radial artery Anatomy 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 102000029752 retinol binding Human genes 0.000 description 2
- 108091000053 retinol binding Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 101000788158 Agelena orientalis U2-agatoxin-Ao1f Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 108010076807 Apolipoprotein C-I Proteins 0.000 description 1
- 102000011772 Apolipoprotein C-I Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 101800003265 Beta-thromboglobulin Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108090000044 Complement Factor I Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 102100035431 Complement factor I Human genes 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108010044063 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101150081880 FGF1 gene Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102400000515 Factor X light chain Human genes 0.000 description 1
- 101800000969 Factor X light chain Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102400000524 Fibrinogen alpha chain Human genes 0.000 description 1
- 101710137044 Fibrinogen alpha chain Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 101000900206 Hantaan virus (strain 76-118) Envelopment polyprotein Proteins 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 101150042788 PROK2 gene Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102100040126 Prokineticin-1 Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 101710203765 Serum basic protease inhibitor Proteins 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 206010041649 Splenic injury Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001957 Ularitide Proteins 0.000 description 1
- 102400001279 Urodilatin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003030 auditory receptor cell Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 102000007329 beta-Thromboglobulin Human genes 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- BGEHHAVMRVXCGR-UHFFFAOYSA-N methylundecylketone Natural products CCCCCCCCCCCCC=O BGEHHAVMRVXCGR-UHFFFAOYSA-N 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 108010025221 plasma protein Z Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108010024107 prekininogens Proteins 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002760 pro-activator Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000024042 response to gravity Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- VLCQZHSMCYCDJL-UHFFFAOYSA-N tribenuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)N(C)C1=NC(C)=NC(OC)=N1 VLCQZHSMCYCDJL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/26—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving
- A61M1/262—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving rotating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/0012—Settling tanks making use of filters, e.g. by floating layers of particulate material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
- B01D21/262—Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/30—Control equipment
- B01D21/34—Controlling the feed distribution; Controlling the liquid level ; Control of process parameters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D24/00—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof
- B01D24/007—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with multiple filtering elements in series connection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D24/00—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof
- B01D24/02—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration
- B01D24/10—Filters comprising loose filtering material, i.e. filtering material without any binder between the individual particles or fibres thereof with the filter bed stationary during the filtration the filtering material being held in a closed container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/246—Membrane extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B1/00—Centrifuges with rotary bowls provided with solid jackets for separating predominantly liquid mixtures with or without solid particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0405—Lymph
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0464—Cerebrospinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0466—Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0496—Urine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/09—Body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/10—Bone-marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2221/00—Applications of separation devices
- B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/10—Specific supply elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/24—Specific pressurizing or depressurizing means
- B01D2313/243—Pumps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/50—Specific extra tanks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/90—Additional auxiliary systems integrated with the module or apparatus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0442—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
- B04B2005/0478—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation with filters in the separation chamber
Definitions
- the present invention is directed to devices and methods for concentrating fluids. More particularly, the present invention is directed to devices and methods for concentrating autologous biological or body fluids.
- Concentration and/or filtration of body fluids have long been practiced in the medical arts. Many medical treatments involve applying a fluid or gel-like substance to a wound or disease location. For some medical treatments, the fluid or gel-like substance is obtained from a body fluid of another person or animal. Body fluids, components of body fluids, or components of other body parts, such as tissue, may also be obtained from other species and used on human patients. Examples of such biological materials which are commonly used in current medical applications on humans are components of mammalian blood and bone, such as allogenic, xenogenic or autogenic graft materials, including from human, bovine and porcine sources.
- the filtration and/or concentration process is carried out in an ongoing, streaming process, wherein the body fluid is simultaneously removed from the patient's body and then downstream returned to the patient's body.
- the filtration and/or concentration process is carried out in a batch process, wherein an amount of the body fluid is removed from the body as a unit, treated, and then returned to the patient's body as a unit.
- body fluids such as blood fractions separated by centrifugation have been further filtered to increase cell or component concentrations in the filtrate.
- U.S. Pat. Nos. 5,733,545, 6,010,627 and 6,342,157 show examples of this, and are incorporated by reference.
- Such concentrated, centrifuged body fluids have been shown to be useful in various treatment modalities, such as applying the concentrated blood component directed to an orthopedic wound site.
- the methods and devices taught in the above patents have shortcomings which have prevented widespread acceptance and use in an operating environment.
- the fluid or gel-like substance obtained from a body fluid of another person or animal is used in treatment and when applied to a patient, increases the risk for infection or diseases such as hepatitis or AIDS.
- autologous body fluids avoids the risk of contracting a disease from external body fluids.
- body fluids or components of body fluids are obtained from other species for use in human treatment, adverse reactions such as allergies, rejection, etc. can occur.
- autologous body fluids also avoids the risk of rejection and other adverse reactions to fluids or tissue from an outside source.
- the present invention includes an apparatus and method for concentrating a fluid, particularly an autologous fluid, for treatment of a patient.
- the concentrator apparatus includes a main housing defining a gravitational separation chamber, a filter housing containing a filter comprising a filter element, a piping for moving concentrated fluid from the separation chamber to the filter housing, and ports for pressurizing the concentrated fluid past the filter element of the filter.
- the gravitational separation chamber is a centrifuge chamber.
- the present invention involves the creation and use of concentrated body fluids.
- a body fluid or tissue is extracted from a patient.
- the extracted substance is separated into different gravitational fractions, such as by centrifuge separation, gravitational weight separation or by mixing the extracted substance with a reagent that causes separation and/or precipitation.
- a portion of the column height is extracted, and then passed through a filter.
- the resultant concentrated, filtered product is then applied to a particular location with the same patient who provided the initial body fluid or tissue, or in a different patient.
- the present invention can be used to treat a variety of conditions.
- the concentrated autologous fluids are used in graft applications, including allograft, xenograft and autograft applications.
- the concentrated autologous fluids can be used to reconstitute freeze-dried or powdered allograft, autograft or xenograft materials.
- the concentrated fluids may also be applied directly to allografts or autografts during implantation, growth factors in the concentrated fluid promoting healing and tissue regeneration after implant surgery.
- the concentrated fluids may be coated onto an allograft material that then binds and/or interacts with reactive functional groups coated onto a polymer core, allowing the allograft to release growth factors in a controlled manner over the period of time required for healing after surgery.
- FIG. 1 is a perspective view of a first embodiment of the invention.
- FIG. 2 is a cross-sectional side view of the embodiment of FIG. 1 taken along lines 2 - 2 .
- FIG. 3 is a cross-sectional side view of the embodiment of FIG. 1 taken along lines 3 - 3 .
- FIG. 5 is a side view of FIGS. 2 and 3 , simplified and modified so as to show all functions on a single view, with arrows A-I indicating the stepwise handling of the body fluid through the inventive device.
- FIG. 6 is a cross sectional side view of a second embodiment of the invention.
- FIG. 7 is a perspective view of a third embodiment of the invention, showing hidden detail in dashed lines.
- FIG. 8 is a cross-sectional view of the embodiment of FIG. 7 .
- body fluid refers to a biological fluid collected from a subject.
- the subject can be a mammal, including but not limited to human, bovine, pig, sheep, horse, or goat.
- the body fluids can be autologous.
- Body fluids include, but are not limited to, blood, plasma, serum, urine, saliva, mucus, cerebrospinal fluid, lymphatic fluid, seminal fluid, amniotic fluid, vitreous fluid, as well as fluid collected from cell culture of patient cells, and the like.
- Body fluids also include tissue such as, for example, bone, bone marrow, muscle tissue, brain, heart, liver, lung, stomach, small intestine, large intestine, colon, uterus ovary, testis, cartilage, soft tissue, skin, subcutaneous tissue, breast tissue, tissue obtained from other species, patient tissue from surgery, and the like.
- the tissue can be disrupted. Methods for disrupting tissue are known and include homogenization and enzymatic treatments.
- the body fluids of the invention also include, for example, bone marrow, fluids obtained from surgery, fluid filtrates, tissue filtrates or fragments, bone chips or fragments obtained during surgery, and the like.
- the term “concentrated” refers to a fluid which has been separated by gravity, centrifugation, and/or filtration into various fractions.
- fraction refers to the various components into which a biological fluid can be separated by centrifugation, gravitational weight separation and/or filtration. Each fraction is richer in a particular fluid component (i.e. concentrated) relative to the other fraction and the original fluid.
- the concentration process also removes nonessential components such that the concentrated fraction contains only necessary or desired components.
- Allograft refers to a tissue or organ obtained from one patient and grafted to a genetically dissimilar patient. When the tissue or organ is obtained from one part of the patient's body and is grafted to another part of the same patient's body, the material is an autograft. Allograft materials include, without limitation, bone, bone powder, bone chips, or bone particles, tendons, ligaments, skin, lens fragments, and the like, obtained from mammalian sources, including bovine, porcine and human sources. Human sources include patients and cadavers. Allograft materials are usually freeze-dried and must be reconstituted in a biocompatible fluid prior to use. Allograft materials may also be substituted with biosynthetic and synthetic materials including, without limitation, demineralized bone matrix, collagen, ceramics, cements, polymers and copolymers.
- growth factor means a bioactive molecule that promotes proliferation of a cell or tissue.
- Growth factors useful in the present invention include, but are not limited to, transforming growth factor-alpha (TGF-alpha), transforming growth factor-beta (TGF-beta), platelet-derived growth factors including the AA, AB and BB isoforms (PDGF), fibroblast growth factors (FGF), including FGF acidic isoforms 1 and 2 , FGF basic form 2 , and FGF 4 , 8 , 9 and 10 , nerve growth factors (NGF) including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, bone growth factors (BGF), basic fibroblast growth factor, insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), EG-VEGF, VEGF-related protein, Bv8, VEGF-E, granulocyte colony stimulating factor (G-CSF),
- Some growth factors can also promote differentiation of a cell or tissue.
- TGF and VEGF for example, can promote growth and/or differentiation of a cell or tissue.
- Some preferred growth factors include VEGF, NGFs, PDGF-AA, PDGF-BB, PDGF-AB, FGFb, FGFa, and BGF.
- differentiation factor means a bioactive molecule that promotes differentiation of cells or tissue.
- the term includes, but is not limited to, neurotrophin, colony stimulating factor (CSF), or transforming growth factor.
- CSF includes granulocyte-CSF, macrophage-CSF, granulocyte-macrophage-CSF, erythropoietin, and IL-3.
- Some differentiation factors can also promote growth or proliferation of a cell or tissue. TGF and IL-3, for example, can promote differentiation and/or growth of cells.
- Chemotactic factors refers to a bioactive molecule responsible for regulating the movement of essential chemicals necessary for proper development, healing and/or homeostasis of cells and tissues.
- Chemotactic factors include cytokines. Cytokines include, but are not limited to, cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5, interleukin (IL) 1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF-alpha, and TNF-beta.
- cytokines include, but are not limited to, cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MG
- adhesion molecule refers to bioactive molecules that promote or facilitate adhesion with other cells or with the extracellular matrix (ECM) or basement membrane (BM).
- Adhesive proteins include actin, fibrin, fibrinogen, fibronectin, vitronectin, laminin, cadherins, selectins, intracellular adhesion molecules 1 , 2 , and 3 , and cell-matrix adhesion receptors including but not limited to integrins such as ⁇ 5 ⁇ 1 , ⁇ 6 ⁇ 1 , ⁇ 7 ⁇ 1 , ⁇ 1 ⁇ 2 , ⁇ 2 ⁇ 3 , and ⁇ 6 ⁇ 4 .
- treatment refers to the process of administering or applying a concentrated biological fluid or concentrated body fluid to a patient at the site of a wound or injury in order to cause or promote healing at the wound or injury site.
- the concentrated fluid can be autologous.
- the concentrated fluid or concentrated body fluid is applied in a therapeutically effective amount. For example, an amount sufficient to cause wound or injury healing when an autologous fluid is applied to a wound or injury site would be a therapeutically effective amount.
- the present invention is directed to concentration of body fluids using a concentrator device, and uses of concentrated body fluids and similar substances produced using the concentrator device. Concentrated body fluids obtained by the methods of the present invention having many uses, including treatment of a variety of medical conditions.
- the present invention includes a fluid concentrator device for concentrating body fluids.
- the body fluids can be autologous body fluids.
- the concentrator 10 of the present invention primarily includes a main housing 12 which defines separation chamber 14 .
- the main housing 12 may be formed as a base plate 16 , a central housing 18 , and a top plate 20 as shown in FIG. 1 .
- the main housing 12 is preferably molded of plastic, but could be formed of any sterilizable material.
- the base plate 16 , central housing 18 and top plate 20 are preferably sealed to each other, such as through an epoxy sealant or sonic welding.
- the base plate 16 , central housing 18 and top plate 20 may alternative be formed with mating threads so as to screw together, and sealed such as with a common O-ring.
- the central housing 18 is transparent or semi-transparent, thereby allowing viewing of the fluid contained within the centrifugation chamber 14 of the central housing 18 . This allows viewing of the body fluid after separation, to better determine which fraction of the fluid to remove from the separation chamber 14 .
- the central housing 18 may include a window, i.e., a portion which is transparent or semi-transparent.
- a biological fluid or body fluid is placed into the chamber 14 and centrifuged, color distinctions between the various components or fractions can be visually discerned.
- the body fluid is blood, platelet poor plasma, buffy coat and red blood cell fractions or components have distinct colors and can be visually distinguished from one another.
- no window is necessary.
- the overall size of the main housing 12 is selected to be compatible with existing centrifuges.
- centrifuges are presently available which handle 4 ⁇ 4 inch vessels, and the main housing 12 is dimensioned to mate with and be received by the common 4 ⁇ 4 inch centrifuge (not shown).
- the main housing 12 is dimensioned to mate with and be received by a 8 ⁇ 8 inch centrifuge.
- the main housing 12 is dimensioned to mate with and be received by a 12 ⁇ 12 inch centrifuge.
- the main housing 12 is dimensioned to mate with and be received by up to a 40 ⁇ 40 inch centrifuge, such as for small volumes up to 250 ⁇ L.
- the bottom wall 22 of the base plate 16 is flat and includes no ports or items projecting from it, so the concentrator 10 can stand on a flat surface and will be stable during centrifugation.
- the top plate 20 includes an opening 24 which serves as a fluid inlet.
- the inlet 24 preferably includes a closure mechanism 26 (shown schematically in FIG. 3 ).
- the closure mechanism 26 could be a rubber stopper, with the fluid hypodermically injected through the rubber stopper into the separation chamber 14 .
- the preferred closure mechanism 26 is a cap with a hand-turnable luer lock, commonly known in the fluid handling art.
- a valve adjustment handle 28 is accessible in the top plate 20
- a valve control handle 30 is accessible in the base plate 16 .
- These two handles 28 , 30 control a valve inlet 32 and valve 34 (shown in FIG. 2 ) which are located within the concentrator 10 .
- the valve adjustment handle 28 allows hand rotation of a threaded valve opening stem 36 , the rotation of which changes the height of the valve inlet 32 relative to the main housing 12 .
- the valve adjustment handle 28 is used to position the valve inlet 32 at a desired height to correspond with the height of the desired fluid layer after separation.
- the valve inlet 32 thus serves as the outlet port to remove a fraction of fluid from the separation chamber 14 .
- a threaded stem 36 provides an easy way of adjusting the height of the valve inlet 32 , many equivalent mechanisms could be used such as a slide, float or other adjustment feature.
- a filter unit 38 is disposed within the separation chamber 14 .
- the filter unit 38 connects between a base port 40 defined in the base plate 16 and a top port 42 defined in the top plate 20 .
- Piping 44 is included to transport the fluid from the valve inlet 32 to the base port 40 or inlet to the filter unit 38 .
- the preferred filter 46 includes a filter housing 48 and a filter element, or membrane.
- the filter element of the present invention comprises a material capable of acting as a separation medium, a filtration medium, or a growth matrix or surface. Separation and/or filtration media include affinity columns, packed bed matrices and beads. Nanofiber networks can be used as filtration media or growth matrix or growth surface. Nanofiber networks and methods of making nanofiber networks are known and commercially available from Surmodics (Minneapolis, Minn.). See, for example, WO 2006/094076, U.S. 2005/0095695 and U.S. 2007/0082393, incorporated herein by reference.
- the filter element comprises a reaction chamber or holding chamber to collect and retain separated fraction and/or filtered fluids or cells.
- the filter element or membrane comprises an affinity membrane, support or column.
- Affinity columns used in chromatographic separation or purification of proteins and other biological macromolecules make use of specific binding interactions between molecules.
- a particular ligand is chemically immobilized or “coupled” to a solid support.
- Ligands that bind to general classes of proteins (such as, for example, receptors or antibodies) or commonly used fusion protein tags (such as, 6 ⁇ His) are commercially available in pre-immobilized forms ready to use for affinity purification.
- more specialized ligands such as specific antibodies, antigens or receptors of interest can be immobilized using one of several commercially available activated affinity supports.
- a peptide antigen can be immobilized to a support and used to purify antibodies that recognize the peptide.
- a receptor that binds a growth factor, differentiation factor, chemotactic factor, or adhesion molecule can be immobilized to a support and used to purify said factors or molecules in the concentrated fraction of body fluids.
- Antibodies and receptors that bind growth factors, differentiation factors, chemotactic factors, or and/or adhesion molecules methods of making such antibodies and receptors, and methods of immobilizing the antibodies and receptors on a support are known.
- One or more ligands can be attached to a filter element of the invention.
- the ligands can be selected to bind one or more particular growth factors, differentiation factors, chemotactic factors, and/or adhesion molecules.
- the ability to attach one or more selected ligands to a filter element of the invention provides for the creation of a custom concentrated body fluid, wherein the particular bioactive molecules comprising the concentrated body fluid are defined, for example, by the particular ligands, concentration of ligands, and/or ratio of one ligand to another selected by the user.
- ligands are immobilized or “coupled” directly to a solid support material by formation of covalent chemical bonds between particular functional groups on the ligand and reactive groups on the support.
- functional groups and reactive groups include, without limitation, primary amines, sulfhydryls, carboxylic acids, aldehydes, and the like.
- other coupling approaches are also possible.
- a GST-tagged fusion protein can be first bound to an immobilized glutathione support by affinity interaction with the GST tag and then chemically cross-linked to the support. The immobilized GST-tagged fusion protein can then be used to affinity purify its binding partner(s).
- the filter element or membrane comprises a packed bed matrix or column.
- a packed bed is a bed of granular material which retains the solid particles as it passes, allowing fluids and liquids to be filtered free of solid contaminants or components.
- the granular material for the packed bed can be sand, although celite or diatomaceous earth packed in a microscale container or loaded on top of a sintered-glass funnel can also serve as the packed bed.
- Incompressible diatomaceous earth i.e. primarily silica
- wood cellulose or other inert porous solids can also be used as the granular material of the packed bed filter.
- a packed bed matrix or column is used as the filtration element of the concentrator device such that when the separated fluid or fluid fraction is passed over the column, solid components or fluid components with a size greater than the pore size of the packed bed material are retained on the packed bed, while other fluid components pass through.
- the filter element or membrane comprises a network of one or more nanofibers, a nanofibrillar structure, glass, silicon, or plastic comprising an etched or micropatterned surface, glass, silicon, or plastic surface comprising macropores or nanopores, or a polymer scaffold.
- Nanofiber networks of this type are described in WO 2006/094076, U.S. 20050059695, and U.S. 20070082393, incorporated herein by reference.
- the nanofiber network can be deposited on a surface of a substrate, and the combination of the nanofiber on the substrate can be a growth matrix or substrate, or as a filtration membrane.
- the nanofiber network comprises a fiber diameter of about 30 nm to about 1200 nm, average interfiber spacing of about 100 nm to about 600 nm, and solidity of about 70 percent or less.
- the nanofibers can be fabricated from a variety of polymers or polymer systems. Preferably the polymer or polymer system is non-cytotoxic.
- the nanofibers are fabricated from a polyamide or polyester.
- the polyamide can be nylon 6, nylon 66, nylon 610 or other biocompatible polyamides.
- the polyester can be poly(c-caprolactone), poly(lactate) or poly(glycolate).
- the polyamide or polyester is suitable for in vivo human application.
- the filter element or membrane can also be a nanofibrillar structure comprising one or more nanofibers.
- the nanofiber network is deposited on a surface of a substrate to provide a growth matrix or surface.
- the substrate can be glass, polymeric, metallic, ceramic, cellulosic, or proteinaceous. Examples of a substrate include but are not limited to a rod, screw, wire, mesh, or cage.
- the substrate can be a surface of a culture container, coverslip, or film.
- the film can be water soluble or water insoluble, biodegradable or biodissolvable. Preferably the film is non-cytotoxic.
- the film comprises polyvinyl alcohol, polychlorotrifluoroethylene, polystyrene, polymethylpentene, or polycylo-olefin.
- the nanofibrillar structure can be utilized singly or layered to form a multi-layered assembly of nanofibrillar structures for cell or tissue culture.
- the nanofibrillar structure comprises a spacer.
- the spacer can function as a support structure.
- the spacer provides sufficient openings to permit cells to penetrate and attach to the nanofiber network.
- the spacer can be water soluble or water insoluble, porous or non-porous, biodegradable or biodissolvable.
- the spacer is biocompatible.
- the nanofibrillar structure is used as a filter element or membrane of the concentrator device, such that when the separated fluid or fluid fraction is passed over the filter element, solid components or fluid components with a size greater than the pore size of the nanofibrillar material are retained on the material, while other fluid components pass through.
- the nanofibrillar structure can be a growth matrix, such that when the centrifuged autologous fluid is passed over the filter element, growth factors in the fluid are retained on the element and can be used to support subsequent cell or tissue growth.
- the separation chamber is configured to accept a filter element or membrane of the invention.
- the filter element or membrane can act as a prefilter to remove unwanted particles or macromolecules from the body fluid prior to separation or during the separation process.
- affinity beads or particles that bind a specific molecule, less of molecules, or particular combination of molecules can be used to remove unwanted particles or macromolecules from a fluid.
- the beads or particles can be added to a biological fluid or body fluid in the separation chamber or the beads or particles can be added to the separation chamber prior to adding the biological fluid or body fluid to the separation chamber.
- the beads can be removed before or after separation.
- a reagent can be added to the separation chamber or biological or body fluid to precipitate out particles or macromolecules.
- the reagent is an antibody or soluble receptor.
- the filter element or membrane of the invention is not tolerant to centrifugation. In such instances, the filter element or membrane is removed from the filter housing 48 and reinstalled into the filter housing 48 after centrifugation.
- the filter membrane has a large number of longitudinally oriented stranded filter lumens 50 .
- the filter strands 50 are sealed with seals 52 to the filter housing 48 at each end.
- the preferred filter strands 50 are about 31 ⁇ 2 inches long, with hundreds of filter strands 50 placed within a 3 ⁇ 4 inch diameter filter housing 48 , to provide a filter area of about 800 cm 2 or more.
- the filter strands 50 preferably have a pass size of about 10 to 30 kDalton through the lumen wall.
- filter strands 50 With these filter strands 50 , the filtrate or retentate moves longitudinally through the lumens 50 and through the filter housing 48 , while water and low molecular weight components (generically called “permeate”) pass through the filter membrane 50 transverse to the filter flow direction.
- Filter strands such as this may be available, for example, from Spectrum Labs of Collinso Dominguez, Calif. or Minntech of Plymouth, Minn.
- the base port 40 and the top port 42 may include female threads (not shown) to receive transfer syringes 54 , 56 shown in FIG. 5 .
- the transfer syringes 54 , 56 are used to apply hand controlled pressure to the separator fluid or fluid fraction to push/pull it through the filter 46 .
- the base port 40 and the top port 42 may be recessed to allow the transfer syringes 54 , 56 to extend inward to the location of the ends of the filter 46 , thereby minimizing the piping distance (and piping volume) from the transfer syringes 54 , 56 to the ends of the filter 46 .
- the transfer syringes 54 , 56 can be operably connected to a pump system used for filtration, such as a vacuum pump system, for example.
- the pump system applies pressure sufficient to allow fluids to pass through the filter element or membrane, without the application of hand-controlled pressure.
- the transfer syringes 54 , 56 can then be used for transfer of separated or filtered body fluid fractions.
- the pump system is equipped with a reservoir for the collection and retention of body fluid fractions that have been separated and/or filtered.
- a concentration detector is installed in line between the filter element and the pump reservoir. The concentration of a filtered fluid fraction can then be readily measured, to determine if additional concentration is required, or whether the fraction needs to be diluted prior to use.
- the concentration detector can be a light-scattering flow cell, absorbance cell or spectrophotometric device.
- the base port 40 and the top port 42 are disposed on the side of the concentrator 10 , oriented transverse to the longitudinal axis 58 .
- This placement allows the base port 40 to be accessible while the concentrator 10 is standing upright on the bottom wall 22 of the base plate 16 , and allows the top port 42 to help balance the base port 40 during transfer of the fluid component through the filter 46 .
- the base port 40 and the top port 42 could be slanted relative to the longitudinal axis 58 , or even extend through the bottom wall 22 of the base plate 16 and top wall 60 of the top plate 20 parallel to the longitudinal axis 58 .
- Placement of the ports 40 , 42 parallel to the longitudinal axis 58 would align the syringe plunger strokes with the direction of fluid movement through the filter 46 , thereby reducing the pressure loss due to piping turns and thereby reducing the risk of damaging the fluid during use of the concentrator 10 .
- a vacuum port 62 connects through the main housing 12 and through the filter housing 48 .
- vacuum pressure 64 shown schematically in FIG. 4
- Vacuum sources 64 are commonly available in environments where the concentrator 10 is utilized. If no vacuum source 64 is available, the vacuum port 62 still serves as a gravitational drain to remove water and low molecular weight components that have passed through the filter membrane 50 . To help vacuum port 62 act as a gravitational drain, it is placed at the bottom of the filter chamber 66 .
- the filter housing 48 is sealed to eliminate fluid communication between the separation chamber 14 and the filter chamber 66 .
- the filter housing 48 may be open to the separation chamber 14 , such that the water and low molecular weight components which pass through the filter membrane 50 proceed into the separation chamber 14 . If the filter housing 48 permits fluid communication between the filter chamber 66 and the separation chamber 14 , then the vacuum port 62 will serve to remove or drain the desired fluid fraction or component as well as water and other low molecular weight components from the concentrator 10 .
- a sample of body fluid (approximately 60 to 80 mL) is placed through the inlet closure 26 and into the separation chamber 14 as shown by arrow A. Preferably, this occurs within minutes after the fluid is withdrawn from the patient. Different amounts or different types of fluid can be alternatively used if the concentrator 10 is used for a different concentration purpose.
- the inlet closure 26 is closed, and the concentrator 10 is centrifuged.
- the centrifugation process is performed in accordance with known centrifuge strategies and velocities, as further described below.
- Transfer syringes 54 , 56 are attached to the base port 40 and the top port 42 .
- the valve adjustment handle 28 is rotated until the height of the valve inlet 32 lines up with the bottom of the fluid layer(s) desired to be further processed.
- the valve 34 is opened using the valve control handle 30 , while the desired fluid layer(s) drain into the base plate 16 and the bottom syringe 54 as shown by arrows B and C. If necessary for pressure relief to enable all of the desired fluid layers to be removed from the separation chamber 14 , the inlet closure 26 may be opened slightly during draining of the desired fluid layers through the valve 34 .
- the inlet closure 26 will incorporate a valve (not shown) allowing for pressure release.
- the valve control handle 30 is used to close off the valve 34 . The unwanted layers are retained in the separation chamber 14 .
- Vacuum pressure is now applied to the vacuum port 62 . Because the remainder of the concentration procedure does not rely on gravitational weight separation, the concentrator 10 device may be placed on its side if desired.
- the vacuum port 62 is preferably located on a side of the central housing 18 opposite the transfer ports 40 ; 42 , thereby providing counterweight and stabilization during transfer of the desired fluid layer(s) through the filter 46 .
- the plunger 68 on the bottom syringe 54 is pushed (while the plunger 68 on the top syringe 56 is optionally being pulled), pushing the desired fluid upward and into the top syringe 56 as shown by arrows D and E.
- the volume of the piping 44 from the valve inlet 32 to the filter 46 , including the bottom syringe 54 , is minimized so as to get as great a yield of concentrated desired fluid from a single starting sample as possible.
- the top port 42 and the base port 40 may include recesses to receive a greater length of the transfer syringes 54 , 56 , and thereby minimize the distance from the end of the transfer syringes 54 , 56 to the inlets to the filter housing 48 .
- the first pass concentrated fluid can be further concentrated by reverse filtering.
- the plunger 68 on the top syringe 56 is pushed (while the plunger 68 on the bottom syringe 54 is optionally pulled), thereby pushing the first-pass concentrated fluid through the filter 46 as shown by arrow I and into the bottom syringe 54 .
- Additional water and low molecular weight components are withdrawn from the first-pass concentrated fluid (arrows F and G).
- the reverse filtering makes additional use of the filter element or membrane 50 and further concentrates the first pass concentrated fluid into “second pass concentrated” fluid. If desired, additional passes may be performed in a like manner.
- the concentrated fluid may be used immediately or after further preparation such as mixing the concentrated fluid with other components, growth factors, differentiate factors, chemotactic factors, and/or adhesion factors suitable for use in various applications.
- the concentrated fluid is mixed with thrombin and then brushed it onto an implant's surface.
- the stranded filters 50 used are single use filter elements, which cannot be effectively cleaned and sterilized. Accordingly, the filter element 46 is disposed of after its single use.
- the entire separation/filtering vessel 10 is sufficiently inexpensive that the entire concentrator 10 unit can be discarded after a single use. This simplifies and/or avoids cleaning of the separation unit and/or filter housing 48 . This also simplifies disposal of the undesired fluid components.
- Filtering within the separation vessel provides further advantages which can be achieved in alternative embodiments. For instance, if the inlet 32 for the drain valve 34 is automatically (rather than visually) positioned at the proper height for the desired fluid layer(s), then the drain valve 34 could be automatically opened using centrifugally activated valves as known in the art. Using similar arrangements, the desired fluid layer(s) can be passed through the filter 46 during centrifugation, using centrifugal forces to push/pull the desired fluid layer(s) through the filter 46 .
- the filter 46 is oriented longitudinally with respect to the centrifugation direction (i.e., with respect to longitudinal axis 58 ). This helps minimize the possibility that the filter strands 50 might pull from their end seals 52 and/or break during centrifugation.
- Alternative embodiments could include orienting the filter strands 50 transversely and at the general height of the desired fluid layer(s), thereby further reducing the piping volume needed to transfer the desired fluid layer(s) to the filter 46 .
- external syringes 54 , 56 are utilized to provide the transfer pressure force for pushing/pulling the desired fluid layer(s) through the filter 46 .
- This provides a low cost method of applying such forces.
- syringes 54 , 56 permit the surgeon to control the amount of pressure versus time on the filtration chamber 66 to force a selected amount of water and low molecular weight components of the centrifuged fraction through the filter membrane 50 .
- the syringes 54 , 56 (including particularly the plunger 68 and slide tube elements 70 ) could be fabricated and/or attached as part of the device.
- the bottom wall 22 of the base plate 16 and the top wall 60 of the top plate 20 could be slidable or depressible similar to the plunger on a syringe, to thereby apply the transfer pressure to push/pull the desired fluid layer(s) through the filter 46 .
- the use of syringes 54 , 56 also allows for the force pushing the desired fluid layer(s) through the filter 46 to be hand controlled by the surgeon or other operator.
- FIG. 6 An additional embodiment of the invention is shown in the concentrator 80 of FIG. 6 . Similar to the first embodiment 10 , the same vessel used in separation is also used to provide filtration. In an embodiment, fluid is centrifuged in the concentrator vessel 80 or subjected to gravitational weight separation in the concentration vessel 80 , and then positive or negative pressure is applied in the same concentrator vessel 80 after separation to force water, low molecular weight components, and other undesired components from the separated fraction resulting in a first pass concentrated component.
- the concentrator vessel 80 includes three chambers 82 , 84 , 86 .
- a separation chamber 82 holds the fluid during separation.
- a water chamber 84 receives water, low molecular weight components and other undesired components removed from the desired fluid layer(s) through the filter 46 .
- a concentrated fluid chamber 86 receives the concentrated fluid which has been filtered.
- the separation chamber 82 preferably holds a float 88 of a particular specific gravity, such as generally equal to the specific gravity of buffy coat.
- the float 88 can be used to aid in positioning of a syringe (not shown) during transfer of the desired fluid layer(s) from the centrifuge chamber 82 to the filter 46 .
- openings in the float 88 can be provided to permit fluid fraction flow therethrough during centrifugation.
- the “shut off” valve 90 for the concentrated fluid chamber 86 may be a variable position valve that would allow the operator to “dial in” the maximum pressure that could be generated in the concentrated fluid chamber 86 , and/or the maximum pressure differential between the water chamber 84 and the concentrated fluid chamber 86 , thereby controlling the concentration of the final output.
- the shut off valve 90 may include a dial with three or more positions connected to something like a butterfly valve or regulator valve, such that the operator selects the desired concentration on the dial then pressurizes the desired fluid layer(s) through the filter 46 to the selected pressure/concentration level.
- a predetermined pressure is generated across the filter 46 that allows for the corresponding amount of water to be removed, thus delivering the desired concentration in one stroke and without the need to fully close off the outport 92 .
- a desired fluid layer(s) isolation chamber 94 is defined between the separation chamber 14 and the filter unit 38 .
- a window valve 96 is added between the separation chamber 14 and the isolation chamber 94 .
- the window valve 96 is ordinarily closed, preventing fluid communication between the separation chamber 14 and the isolation chamber 94 .
- the window valve 96 has a locking mechanism 98 , which also acts as a valve handle.
- a lock 100 prevents the lock handle knob 102 from being pushed down, thereby preventing the windows 104 from being pushed down into communication with the separation 14 during separation, such as.
- the lock handle knob 102 is rotated 90° to a position where the lock 100 lines up with a keyway 106 , enabling the knob 102 to be pushed downward against a spring 108 .
- the windows 104 are attached to and controlled by the knob 102 , and pushing the lock handle knob 102 downward moves the windows 104 downward into communication with the separation chamber 14 .
- the desired fluid layer(s) of the separated fluid flow by gravity from the separation chamber 14 into the isolation chamber 94 .
- the knob 102 is released, with the spring 108 moving the windows 104 upward and closing communication between the isolation chamber 94 and the separation chamber 14 .
- the isolation chamber 94 holds the desired fluid layer(s) until subsequent processing, such as filtration.
- the isolation chamber 94 defines the volume of the desired fluid layer(s) which will be removed from the starting fluid unit and filtered. Placement of the desired fluid layer(s) within the isolation chamber 94 allows the concentrator 10 to be handled without fear of remixing the desired fluid layer(s) into the remainder of the starting fluid. For example, after the desired fluid layers(s) are moved into the isolation chamber, the concentrator 10 can be placed on its side prior to fluid filtration.
- the isolation chamber 94 also permits a delay time between separation and filtering.
- the desired fluid layer(s) can optionally be further treated while in the isolation chamber 94 .
- additives may be mixed with the fluid within the isolation chamber 94 , particularly if the additives enhance the filtration process, such as by having the additives in the isolation chamber 94 prior to opening the window valve 96 .
- a twist valve 110 is opened to open communication between the isolation chamber 94 and the base port 40 and the filter unit 38 .
- the desired fluid layer(s) are withdrawn from the isolation chamber 94 through the twist valve 110 with a syringe 54 , at which point the twist valve 110 is closed.
- the plunger stroke on the syringe 54 is then reversed to push the desired fluid layer(s) through the filter unit 38 .
- the syringes 54 , 56 for pressuring the fluid layer(s) through the filter unit 38 can have a much lower volume than the isolation chamber 94 (say, for instance, 1 ⁇ 3 the volume). Then fluid can be removed from the isolation chamber 94 in portions (1 ⁇ 3 at a time) which are filtered separately, one portion at a time.
- Portioning of the desired fluid layer(s) through the filter unit 38 is particularly advantageous in situations wherein preparation steps are taken for the filter 46 between portions. For instance, if the filter 46 is becoming clogged while only filtering 1 ⁇ 3 of the fluid volume in the isolation chamber 94 , a purge fluid could be pressured through the filter 46 to unclog the filter 46 prior to filtering the second portion through the filter 46 . After the first portion has been filtered and the filter 46 purged, the twist valve 110 is reopened to remove a second portion. The twist valve 110 is then reclosed to permit filtering of the second portion, followed by any purging of the filter 46 . Because the twist valve 110 controls communication between the isolation chamber 94 and the base port 40 , fluid may thus be removed from the isolation chamber 94 in whatever size portions are desired.
- a syringe having a plunger is provided to pull (negative pressure) the component out of the centrifuged starting fluid (i.e. the original fluid sample).
- the syringe also houses a filter 46 , and the plunger stroke is reversed to push (positive pressure) the component through the filter 46 and separate the component into water and a concentrated retentate.
- the surgeon or other operator controls the pressure and/or duration of the filtration step, and thus the surgeon or other operator controls how concentrated the concentrated retentate is relative to the separated component, as well as how hard the fluid is worked during the filtration step.
- a concentrator device of the invention can be used to separate organelles, cells or proteins, in addition to concentrating body fluids. Separation can be performed by centrifugation or gravitational weight separation.
- the body fluids may be autologous body fluids.
- Centrifugation is a process used to separate or concentrate materials suspended in a liquid medium. The theoretical basis of this technique is the effect of gravity on particles (including macromolecules) in suspension. Two particles of different masses will settle in a tube at different rates in response to gravity. Centrifugal force (g) is used to increase this settling rate, and the means to increase the rate is a centrifuge.
- centrifugal force generated is proportional to the rotation rate of the rotor (in RPM) and the distance between the rotor center and the centrifuge tube. Therefore, a given centrifuge may use multiple rotor sizes to give flexibility in choosing centrifugation conditions.
- Rotors for centrifuge devices are either fixed angle, swinging bucket, continuous flow, or zonal, depending upon whether the sample is held at a given angle to the rotation plane, is allowed to swing out on a pivot and into the plane of rotation, designed with inlet and outlet ports for separation of large volumes, or a combination of these.
- the methods of the present invention use continuous flow centrifugation for separation and concentration of large fluid volumes. Continuous flow centrifugation can also be used for the large scale separation of particles on density gradients.
- These rotors can contain up to 2 L of fluid and can work with tissue samples measured in ounces. The rotors are brought up to about 3000 RPM while empty, and the density media and tissues are added through specialized ports.
- the rotors are used in ultracentrifugation processes, and contain small volumes of fluid, up to 250 mL.
- the rotors can be used for laboratory manipulations where only small fluid volumes or tissue amounts are available.
- the rotors are brought up to 15,000-18,000 RPM with a maximum of 20,000 RPM.
- Rotors for standard centrifugation can range from 4 by 2 or 2.5 L to 40 by 250 ⁇ L.
- rotors can range from 6 by 250 mL to 72 by 230 ⁇ L, with wide intermediate ranges such as, for example, 8 by 6.8 mL, 6 by 94 mL, 6 by 4 mL, 8 by 5.1 mL, and 8 by 39 mL.
- the main housing of a fluid concentrator of the invention can be dimensioned to mate and be received by a standard centrifugation rotor or ultracentrifugation rotor. As with standard centrifugation, the rotors can be brought up to speed while empty, with the media, samples and tissues introduced through special ports.
- the concentrator of the invention can be used to separate proteins or cells by density gradient centrifugation.
- density gradients is routine in centrifugal fractionation of particle mixtures, cells mixtures, and purification of subcellular organelles and macromolecules, including proteins.
- a particle can be a macromolecule or cell.
- the mixture of particles to be separated is placed onto the surface of a vertical column of liquid, the density of which progressively increases from top to bottom, and then centrifuged. Although the particles in suspension are individually denser than the liquid at the top of the gradient, the average density for the sample (i.e. particles plus suspending liquid) is lower.
- the two main types of density gradient centrifugation are rate-zonal separation and isopynic separation.
- In rate-zonal separation particles are separated based on their size and mass.
- the particles migrate through the gradient until they reach the point at which their size and mass match that of the gradient.
- This centrifugation method is useful in separating out particles with the same or very similar densities, but different masses. Many proteins, such as antibodies, for example, may be separated in this way. Protein separation by centrifugation can be predicted by simulation software, such as EPS Rate Zonal Run (Beckman Coulter, Fullerton Calif.).
- Isopycnic gradients include cesium chloride gradients, for example.
- Density gradients can be used to affect protein or cell separation using a concentrator device of the invention.
- the gradient can be built up in the centrifuge rotors or tubes, carefully layering one step on another, beginning with the densest step, by use of a pipette, or other mechanical or syringe means.
- the gradient can be formed beginning with the least dense step by depositing each layer at the bottom of the centrifuge chamber through a narrow cannula or by other mechanical or syringe means.
- Continuous density gradients are gradients in which the density changes smoothly and continuously from one limit or extreme to another. Such gradients can be produced from step gradients by allowing sufficient time for diffusion to smooth out the steps, but continuous gradients are normally prepared directly by using special devices known as gradient makers or gradient engines.
- Body fluids can be concentrated using a concentrator device of the invention by density gradient methods.
- the body fluids are autologous body fluids.
- the density gradient and the separated particles, cells or proteins and desired fluid layer(s) can be removed from the rotor and collected as a series of fractions.
- one or more fluid fractions collected from the concentrator device correspond to concentrated body fluids.
- concentrated body fluids can be prepared by centrifugation or gravitational weight separation including, without limitation, blood fractions (platelet rich plasma (PRP), platelet poor plasma (PPP)), stem cells (cord blood-derived and bone marrow-derived) for example, concentrated seminal fluid, concentrated spinal fluid and the like.
- the fluid fractions are concentrated to concentrations of about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:100, about 1:200, about 1:500, or about 1:1000.
- the one or more components in a concentrated fluid fraction is concentrated about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:100, about 1:200, about 1:500, or about 1:1000 compared to the same one or more components in the unconcentrated fluid.
- the fluid fractions are concentrated to concentrations from about 1:20 to about 1:50, from about 1:20 to about 1:100, from about 1:50 to about 1:100, from about 1:50 to about 1:200, from about 1:100 to about 1:200, from about 1:200 to about 1:500, from about 1:200 to about 1:1000, or from about 1:500 to about 1:1000.
- one or more components in a concentrated fluid fraction is concentrated from about 1:20 to about 1:50, from about 1:20 to about 1:100, from about 1:50 to about 1:100, from about 1:50 to about 1:200, from about 1:100 to about 1:200, from about 1:200 to about 1:500, from about 1:200 to about 1:1000, or from about 1:500 to about 1:1000 compared to the same one or more components in the unconcentrated fluid.
- the concentrator of the invention preserves or maintains the physiological ratios of the components in the body fluid fraction. The exact ratio of each component is not significant, as long as the relative physiological ratios are maintained during concentration.
- a concentrated and filtered fraction of autologous fluid obtained by a concentration device of the invention is administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, or about 4 hours from the time of isolation of the antilogous fluid from the subject.
- Concentrated body fluids obtained by the methods of the invention can be used in a wide variety of applications, including, without limitation, surgical applications, preparation of allograft materials for implants, tissue regeneration or tissue culture, stem cell growth or separation, seminal fluid fractionation, protein separation, and DNA purification.
- the concentrated biological fluids of the invention are autologous body fluids.
- the concentrator of the invention can be used to obtain concentrated fractions of blood or plasma, including platelet rich plasma (PRP) and platelet poor plasma (PPP).
- the concentrator of the invention is used to obtain concentrated PRP from a sample of patient blood during surgery for use in surgical applications, such as bone healing.
- whole blood is withdrawn from the patient, and centrifuged in the concentrator of the invention for 5 to 30 minutes at 25 to 1000 g, and in another embodiment, the whole blood is centrifuged for about 15 minutes at 400 g.
- the central PRP layer of the centrifuged blood is visually identified by color and withdrawn from the separation chamber.
- the PRP layer is passed through the filter unit under syringe pressure for one to ten passes, and in an embodiment, the PRP layer is passed through the filter for 6 passes.
- the filtration can be tangential flow or dead end.
- tangential flow filtration using hollow filter fiber membranes with a size cutoff of 0.1 nm to 100,000 nm and a surface area of 1 cm 2 to 6000 cm 2 is used. This results in the production of concentrated PRP.
- the concentrated PRP obtained has a thick, gel-like consistency, having an increased concentration of platelets and white blood cells as compared to whole blood. With the higher concentration of platelets, the resultant material includes a higher concentration of growth factors from the blood.
- the resultant concentrated PRP product can be directly applied to, for example, a fractured or damaged bone during surgery, a wound, a surgical incision, or damaged tissue.
- the concentrated PRP obtained by the concentrator can be a bone growth stimulant applied directly to the injured or fractured bone, wound, surgical incision or damaged tissue.
- the higher concentration of the patient's own growth factors obtained from the patient's blood induce a faster healing rate for the bone, reduce low grade infection around the surgical site or wound, and reduce soft tissue inflammatory response.
- various known diluents such as buffered saline, may be used to adjust the viscosity of the autologous concentrated PRP for various applications.
- a concentrator of the invention is used to obtain concentrated PRP from a sample of patient blood during surgery, for use in surgical applications such as cartilage healing.
- the resultant concentrated PRP product is surgically applied directly to a site of damaged, wounded or severed cartilage.
- the concentrated PRP can be mixed with chondrocytes obtained from the patient or a different source.
- chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage with pronase and collagenase.
- the cartilage is autogenic/autologous, allogenic or xenogenic.
- the cartilage is derived from mammalian sources, including human, porcine and bovine sources.
- the concentrated PRP can also be mixed with artificial polymer or collagen-based cartilage replacement products to improve integration of the cartilage defect repair substance and to enhance anchoring of the cartilage defect repair substance.
- the concentrated PRP obtained by the concentrator of the invention as a cartilage repair growth stimulant directly to the cartilage site, the higher concentration of growth factors obtained induces a faster healing and ingrowth rate for the cartilage, reduce low grade infection around the surgical site, and reduce soft tissue inflammatory response.
- the concentrated PRP is an autologous fluid obtained from the patient's own blood.
- concentrated PRP is obtained as described above, and the concentrated PRP is applied either between two locations of soft tissue such as at a surgical incision, in between stitched tissue, etc., or as a salve or balm over a section of damaged soft tissue, such as over a burn site, laceration or abrasion.
- Concentrated PRP used as a salve or balm causes delivery of additional growth factors and blood proteins to the tissue healing site, resulting in faster wound closure and healing.
- the concentrated PRP used in a salve or balm for soft tissue healing induces or promotes an effective increase in one or more of cytoplasmic granules, serotonin, ADP, Thromboxane A 2 , factors III, V, VII, X, XI and/or XII, platelet thromboplastic factor (PF 3 ), and prothrombin activator.
- the concentrated PRP of the invention is used as a platelet glue wound sealants. These sealants are discussed in U.S. Pat. Nos. 5,733,545, 6,010,627 and 6,342,157, incorporated by reference.
- Concentrated PRP can be obtained by a concentrator of the invention as described above.
- the resultant concentrated PRP is a sticky gel-like material, which can be used similar to surgical glue to adhere two tissue portions together.
- concentrated PRP of the invention can be mixed with other surgical glue materials to increase the adhesive characteristics, increase the yield volume, and/or adjust the spreadability of the resultant mixture.
- tissue adhesives is fibrin-based and contains a concentrate of fibrinogen and thrombin.
- the fibrin adhesives are typically two-component adhesives that when mixed together react to simulate the last stages of the clot-forming cascade. The resulting clot adheres to tissue and bridges a gap therebetween until healing can occur.
- the concentrated PRP of the present invention can be mixed with any of these known biologically presourced, tissue adhesives.
- the concentrated PRP in the surgical glue causes delivery of additional growth factors and blood proteins to the tissue healing site, resulting in faster wound closure and healing. While not wishing to be bound by a particular theory, it is believed that the concentrated PRP used in a salve or balm for soft tissue healing induces or promotes an effective increase in one or more of cytoplasmic granules, as described above with regard to concentrated PRP used as a salve or balm.
- the concentrator of the invention is used to obtain concentrated PPP from a sample of patient blood during surgery.
- whole blood is withdrawn from the patient, and centrifuged in the concentrator of the invention for 2 to 30 minutes at 250 to 10000 g.
- withdrawn blood from the patient is centrifuged in the concentrator of the invention for about 5 minutes at 6500 g.
- the PPP layer of the centrifuged blood is visually identified by color and withdrawn from the centrifuge chamber.
- the PPP is passed through the filter unit under syringe pressure for one to ten passes, and in an embodiment, for 4 passes.
- the PPP can be cooled prior to filtration to accelerate precipitation separation, such as down to 1 to 10° C.
- the filtration results in a concentrated PPP.
- the concentrated PPP obtained is a viscous liquid, having an increased concentration of fibrinogen, thrombin, clotting factors and associated proteins and structures as compared to whole blood.
- Various known diluents such as buffered saline, can be used to adjust the viscosity of the autologous concentrated PPP for various applications.
- the resultant concentrated PPP product can be used as an essential ingredient in formulating a high fibrin glue. If a cooling step was applied to the platelet poor plasma, the high fibrin glue can be reheated to about 37° C. for application to the patient.
- the high fibrin glue can be mixed with commercially available sealant preparations, such as TISSEEL from Baxter International of Deerfield, Ill. or with cyanoacrylate tissue adhesives such as DERMABOND of Ethicon of Somerville, N.J.
- sealant preparations such as TISSEEL from Baxter International of Deerfield, Ill. or with cyanoacrylate tissue adhesives such as DERMABOND of Ethicon of Somerville, N.J.
- cyanoacrylate tissue adhesives such as DERMABOND of Ethicon of Somerville, N.J.
- the high fibrin glue helps produce a stable, flexible and elastic fibrin bioactive matrix, which firmly adheres to exposed collagen, similar to those formed more slowly during physiologic blood coagulation.
- the autologous PPP glue of the present invention can also be mixed with glues based on gelatin cross-linked with an aldehyde, such as gelatin-resorcinol cross-linked with formaldehyde (GRF) or glutaraldehyde (GRFG), or with tissue glues derived from cyanoacrylates, polyurethanes, polymethylmethacrylates, among other synthetic polymers.
- an aldehyde such as gelatin-resorcinol cross-linked with formaldehyde (GRF) or glutaraldehyde (GRFG)
- tissue glues derived from cyanoacrylates, polyurethanes, polymethylmethacrylates, among other synthetic polymers such as gelatin-resorcinol cross-linked with formaldehyde (GRF) or glutaraldehyde (GRFG)
- the high fibrin glue can be used during surgery, such as during thoracic, cardiovascular, and general surgical operations, and in orthopedic procedures such as fixation of chondral fragments, chondral chips and osteochondral fragments.
- the high fibrin glue can also be used as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of splenic injuries due to blunt or penetrating trauma to the abdomen, when control of bleeding is important.
- the high fibrin glue can also be used for incisional or laceration repair.
- the high fibrin glue can also be used to adhere drug delivery matrices, or other such overlays that can be used in conjunction with autograft, allograft, or xenograft materials, such as ligaments, bone tissue, skin, tendons, cartilage and the like.
- concentrated PPP obtained by the methods of the invention is used for cartilage healing.
- Concentrated PPP is obtained as described above.
- the concentrated PPP can be applied as a cartilaginous repair material directly to a cartilage defect.
- the concentrated PRP can be mixed with chondrocytes obtained from the patient or a different source.
- chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage with pronase and collagenase.
- the concentrated PPP can also be mixed with artificial polymer or collagen-based cartilage replacement products to improve integration of the cartilage defect repair substance and to enhance anchoring of the cartilage defect repair substance.
- a concentrator of the invention can be used, for example, to obtain concentrated fluids or concentrated autologous fluids such as autologous concentrated PRP, PPP, growth factors, differentiation factors, chemotactic factors, adhesion molecules, or stem cells for use in surgical applications.
- a graft material is an allogenic or xenogenic material, derived from mammalian sources including human, bovine and porcine sources.
- autologous concentrated PRP, PPP, growth factors, differentiation factors, chemotactic factors, adhesion molecules, stem cells, or a combination thereof are applied to an organ or tissue from a genetically non-identical donor prior to or during transplanting of the organ or tissue.
- Such application to the allograft or xenograft results in increased acceptance of the new organ or tissue from the recipient's immune system and decreased rejection, aids in regeneration of tissue around the new organ or tissue, and further helps decrease healing time from the transplant surgery.
- a concentrator of the invention can be used to obtain a concentrated fluid containing one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules or a combination thereof from a body fluid for use in the preparation of graft materials for implantation.
- the concentrated fluid is PRP, PPP, or PRP+PPP.
- the concentrated fluid is autologous.
- the graft material can be coated to provide controlled release of proteins such as one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or combination thereof from a surface of the graft material.
- the graft material can be coated with a layer of polymeric material.
- Solubility or insolubility of the polymeric material can be engineered to control the release the one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or combination thereof of bioactive molecules from the polymeric coating.
- the rate of release is determined by the rate of degradation and/or dissolution of the polymer or copolymer comprising the coating.
- the polymer layer comprises one or more reactive functional groups that can react with or covalently bind one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or a combination thereof present in the concentrated autologous fluid.
- suitable polymeric materials include but are limited to EUREKA DUET in-situ forming matrix, EUREKA DUET biodegradable device matrix, ENCORE drug delivery polymer matrix, SYNBIOSYS biodegradable drug delivery polymer system, CAMEO biodegradable polymeric drug delivery matrix, POLYACTIVE biodegradable polymeric drug delivery matrix, CELLABRATION encapsulation polymer matrix, and PHOTOLINK (Surmodics, Minneapolis, Minn.).
- the concentrated body fluid or autologous fluid can be used to reconstitute graft material, which is typically in a freeze-dried form. Reconstituting the graft material with an autologous concentrated fluid such as PRP provides increased acceptance of the tissue at the transplant site and speeds healing after graft surgery.
- a coating agent comprises a nonpolymeric core molecule having attached thereto, either directly or indirectly, one or more substituents comprising negatively charged groups or reactive species that can interact with positively charged moieties on growth factors, differentiation factors, chemotactic factors, adhesion molecules and the like in the concentrated fluid.
- the coating agent comprising a nonpolymeric core molecule having attached thereto, directly or indirectly, one or more substituents comprising negatively charged groups or reactive species that can interact with positively charged moieties of one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or a combination thereof.
- reactive species comprise one or more first reactive species adapted to attach the coating to a surface, and one or more second reactive species adapted to initiate polymerization.
- the polymer layers are coated with biodegradable layers of nanoscale polysaccharides, antimicrobial agents, antifungal agents, biologically active macromolecules, such as proteins, peptides and amino acid analogs, for example, and the like.
- the polymer layers are coated with cells, cell agglomerates or cell matrices. The polymer layers and methods for making such polymer layers are known in the art, and are further described in, for example, U.S. Pat. No. 6,514,734, incorporated herein by reference.
- the graft material is coated with a nanofiber or microfiber.
- the nanofiber or microfiber comprises one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or a combination thereof.
- the molecules can be attached to the surface of the fiber, such as for example by a functional group or charged moiety, or added to the polymer solution prior to electrospinning.
- functional groups are deposited on the growth surface by plasma deposition. Plasma deposition creates local plasmas on the surfaces of the fibers. The treated surface is then reacted with gaseous molecules, such as allylamine and/or allyl alcohol, in a reaction chamber.
- functional groups are introduced during manufacturing of the fibers.
- dodecyl amine, dodecyl aldehyde, dodecyl thiol, or dodecyl alcohol can be added to a polymer solution during the manufacturing process. A portion of the added amines, aldehydes, sulphydryl, or alcohol moieties, respectively, are exposed at the surface of the fiber.
- suitable nanofibers and microfibers are described, for example, in U.S. 2005/0059695, WO 2006/094076, U.S. 2007/0082393, and are commercially available, for example, from Surmodics (Minneapolis, Minn.).
- Solubility or insolubility of the nanofibers or microfibers can be engineered to control the release the one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or combination thereof of bioactive molecules from the nanofibers or microfibers.
- the rate of release is determined by the rate of degradation and/or dissolution of the polymer or copolymer comprising the nanofiber or microfiber.
- above void filter such as demineralized bone matrix (DBM) is reconstituted in and/or coated with a concentrated fluid obtained from a concentrator of the invention.
- the fluid is concentrated autologous PRP.
- the concentrator can used to obtain concentrated PRP from a sample of patient blood during surgery.
- the concentrated PRP can be mixed with a bone void filler, such as DBM.
- Suitable DBMs can be obtained from LifeNet of Virginia Beach, Va.
- the resultant mixture is applied during surgery in any of numerous applications, including, without limitation, spinal fusion, spinal defects, trauma, bone cysts, bone tumors, fracture management, filling of osseous defects, augmenting total joints, sinus augmentation, ridge preservation, joint revisions, posterolateral fusion procedures and general orthopedics applications.
- Mixing the patient's own concentrated PRP with bone void filler for surgical application back into the patient results in increased osteoconductivity and faster bone growth.
- the bone void filler material is more likely to be readily accepted by the patient's immune system and a lower chance of rejection, and aids in regeneration of bone tissue around the bone void filler material.
- Concentrated fluids obtained by the methods of the invention can be used in tissue regeneration, tissue culture, and cell culture.
- Concentrated fluids comprising one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or a combination thereof can be added to a growth matrix or added directly to tissue or cell culture media.
- the concentrated fluid is applied to the site of a wound or injury in order to promote proliferation of cells and repair and regeneration of tissue in the wound site.
- the filter housing of a concentrator of the invention can be configured as a growth chamber.
- the filter housing is fitted with a growth matrix or growth surface.
- a growth matrix or growth surface include but are not limited to a network of one or more nanofibers, a nanofibrillar structure, glass, silicon or plastic comprising an etched or micropatterned surface, glass, silicon or plastic surface comprising macropores or nanopores, a polymer scaffold, a woven scaffold, a woven or net textile, an extruded scaffold, a rod, a screw, a wire, a mesh, or a cage.
- the growth matrix or growth surface can be glass, polymeric, metallic, ceramic, cellulosic, or proteinaceous.
- a surface of the growth matrix is coated with nanofibers or a polymeric coating that supports the growth and/or attachment of cells seeded on or to the surface.
- a suitable surface includes, but is not limited to, a surface of a rod, screw, wire, mesh, or cage. Examples of nanofibers and/or polymeric coatings that support the growth and/or attachment of cells to or on a coated surface are described herein and are known in the art.
- the growth matrix is a nanofibrillar structure.
- the nanofibrillar structure can be layered to form a multi-layered nanofibrillar assembly.
- a diverse array of growth environments for a cell or tissue can be constructed by engineering specific chemical and physical properties into the nanofiber network, substrate, and/or spacers comprising the individual nanofibrillar structure and/or sequentially layering individual nanofibrillar structures.
- Specific nano- and/or micro-environments can be engineered within individual nanofibrillar structures or within an assembly comprising two or more layered nanofibrillar structures.
- Physical properties and/or characteristics of individual nanofibrillar structures including, but not limited to, surface roughness, adhesivity, porosity, solidity, elasticity, geometry, interconnectivity, surface to volume ratio, fiber diameter, fiber solubility/insolubility, hydrophilicity/hydrophobicity, fibril density, and fiber orientation can be engineered to mimic the nanotopography of ECM or BM.
- the physical and geometric properties of the nanotopography of the individual nanofibrillar structures of the assembly can be engineered to mimic the nanotopography of the extracellular matrix or basement membrane.
- Specific recognition motifs such as peptides, polypeptides, lipids, carbohydrates, amino acids, nucleotides, nucleic acids, polynucleotides, or polysaccharides including, but not limited to, growth factors, differentiation factors, fibrous proteins, adhesive proteins, glycoproteins, functional groups, adhesive compounds, and targeting molecules can be engineered into the nanofibrillar network, substrate, and/or spacers of the individual nanofibrillar structures or multi-layered assembly either isotropically or as gradients to promote appropriate cellular activity, including cell growth and/or differentiation.
- Embodiments involving amino acids, peptides, polypeptides, and proteins can include any type of such molecules of any size and complexity as well as combinations of such molecules. Examples include, but are not limited to, structural proteins, enzymes, growth factors, differentiation factors, and peptide hormones.
- Nanofibrillar growth matrices and methods of using growth matrices for cell proliferation and differentiation and culturing cells or tissue are described in detail, for example, in U.S. 20050095695 and WO 2006/094076, incorporated herein by reference.
- a fluid, cells, or tissue is added to the separation chamber of a concentrator of the invention and the concentrator is centrifuged or separated by gravitational weight.
- the tissue is disrupted tissue.
- the fluid, cells, or tissue are autologous.
- a desired cellular fraction is removed from the separation chamber and transferred via the transfer ports to the filter chamber comprising a growth matrix.
- the cells can be cultured on the growth matrix within the concentrator or the growth matrix can be removed and cultured separately.
- Cells or tissue can be grown on the growth matrix in vivo, in vitro, or ex vivo using known methods and conditions.
- Cells useful in the methods of the invention include stem cells, somatic cells, committed stem cells, differentiated cells, and tumor cells.
- the cells can be from a mammal.
- the mammal can be human.
- the cells can be a tissue. Examples of tissue include skin, bone, liver, heart, kidney, bladder, muscle, ligament, tendon, cartilage, brain, retina, cornea, and pancreas.
- Examples of cells useful in the methods of the invention include, but are not limited to, osteoblasts, myoblasts, neurons, fibroblasts, glioblasts, germ cells, stem cells, hepatocytes, chondrocytes, keratinocytes, smooth muscle cells, cardiac muscle cells, connective tissue cells, glial cells, epithelial cells, endothelial cells, hormone-secreting cells, neurons, and lymphoid cells such as B cells, T cells, macrophages, and neutrophils.
- Examples of stem cells include, but are not limited to, embryonic stem cells, mesenchymal stem cells, bone marrow stem cells, and umbilical cord stem cells.
- the stem cells can be mammalian stem cells.
- the stem cells are human.
- the stem cells are embryonic stem cells.
- the cells can be from the recipient, a nonspecific donor from the same species, or a donor from a different species.
- the cells can be from the tissue of a transgenic animal wherein the cell has been engineered to express one or more polynucleotides, repress the expression of one or more polynucleotides, or both.
- An example of genetically engineered cells useful in the methods of the present invention is cells engineered to make and secrete one or more desired bioactive molecules. When these cells are implanted in an organism or patient, the bioactive molecules produced by the cells can produce a local effect or a systemic effect. Examples of bioactive molecules include growth factors, differentiation factors, and hormones.
- hormones include insulin, human growth factor, erythropoietin, thyroid stimulating hormone, estrogen, or progesterone.
- Cells can be engineered to produce an antigen. These cells can be implanted into an organism or patient to produce an immune response. Cells can be engineered to produce bioactive molecules that inhibit or stimulate inflammation, facilitate healing, resist immuno-rejection, provide hormone replacement, replace neurotransmitters, inhibit or destroy cancer cells, promote cell growth, inhibit or stimulate formation of blood vessels, augment tissue, and promote or induce supplementation or replacement of skin, synovial fluid, tendons, cartilage, ligaments, bone, muscle, organs, dura, blood vessels, bone marrow, and extracellular matrix.
- Genetic engineering can involve, for example, adding or removing genetic material to or from a cell, altering existing genetic material, or both using standard recombinant methods.
- Embodiments in which cells are transfected or otherwise engineered to express a polynucleotide can use transiently or permanently transfected polynucleotide, or both.
- Polynucleotide sequences can be full or partial length, cloned or naturally occurring.
- the concentrated fluid of the invention is a fluid comprising bone marrow-derived stem cells.
- the concentrated fluid is autologous.
- a surgeon inserts a large needle directly into the bone marrow cavity of bones of the lower back, of a patient and aspirates bone marrow out of the bones by inserting the needle into the bone multiple times.
- the aspirated bone marrow is then centrifuged in a concentrator of the invention, such as at 400 g for 5 minutes.
- the aspirated bone marrow is a blood-like substance with sufficiently different cell and molecule sizes and weights that the centrifuging process induces separation of the bone marrow into different fractions.
- the aspirated bone marrow can be mixed with 0.56% (0.075 M) KCl (0.56 g in 100 ml deionized water).
- the bottom layer is then removed and filtered at 1 to 10 and preferably 4 passes through the filter.
- the layers are filtered using a filtration system comprising a filter element or membrane as described elsewhere in this Application.
- the concentrated fluid is a fluid comprising cord blood-derived stem cells.
- blood is obtained from an umbilical cord during birth.
- the cord blood can be centrifuged in a concentrator of the invention, such as at 400 g for 5 minutes, thereby inducing separation of the cord blood into different fractions.
- the bottom layer is removed and filtered at 1 to 10 and preferably 4 passes through the filter, thereby obtaining a substance with an increased concentration of cord blood derived stem cells.
- the layers are filtered using a filtration system comprising a filter element or membrane as described elsewhere in this Application.
- the collection window of the device is infinitely adjustable along the column of the centrifuged body fluid, allowing more accurate collection of the concentrated autologous bone-marrow-derived stem cells.
- the fluid collected with the stem cells can be used for binding the cells and chips bone material.
- the fluid collected with the stem cells also helps maintaining the viability of the stem cells for a longer period of time by maintaining a consistent environment for the stem cells.
- the resulting concentrated stem cells are then injected or applied within a patient at a particular location of interest.
- the stem cells are injected or administered with a carrier, such as DBM.
- a carrier such as DBM.
- concentrated stem cells can be injected into the brain as a treatment for brain damage or into or adjacent the spinal cord after a spinal cord injury or disease such as ALS (Lou Gehrig's disease).
- the concentrated stem cells can be injected into a muscle which has undergone muscle damage, particularly into the heart such as for the treatment of non-ischemic (idiopathic) and ischemic heart failure.
- the stem cells can be injected into the circulatory system or back into the bone marrow to increase red blood cell production.
- the concentrated stem cells can be placed into the gums to form tooth buds, can be placed into the cochlea to induce cochlear hair cell regrowth as a treatment for deafness, or can be transplanted over a damaged retina as a treatment for blindness.
- the concentrated stem cells can be topically applied to treat a soft tissue wound or burn or similar injury.
- the concentrated stem cells can be added to an injured or fractured bone to facilitate bone healing.
- the concentrated stem cells can also be used for diagnosis purposes.
- a concentrator and methods of the invention can be used for sperm selection.
- the concentrator device can be used to collect sperm and select either X- or Y-genotype sperm from a sample of mammalian seminal fluid. These methods are predicated on the fact that the two sperm genotypes of mammals (X and Y) may be separated according to pH or density characteristics.
- the sperm is obtained from a livestock mammal, such as a bovine, horse, pig, sheep, or goat. For separation by density characteristics, application of buoyant forces within a liquid separation medium causes more buoyant sperm to obtain a different level in the separation medium than less buoyant sperm.
- the fluid When a sample of seminal fluid is centrifuged using the device of the invention, the fluid is separated into fractions containing either the X or the Y-genotype sperm because of the difference in density of each genotype.
- the sample of seminal fluid is a sample from a human patient
- separation into X and Y-genotype sperm requires the application of a pH gradient in the concentrator of the invention.
- Substantially pure sperm fractions (having either X or Y-genotype characteristics) are isolated as either the top layer or the bottom layer of the concentrated fluid obtained from the device of the invention.
- separation of the sperm into fractions or concentration in one particular genotype is enhanced by the application of pressure (positive or negative) to the filtration element or filter membrane of the device.
- pressure positive or negative
- Methods for density separation of sperm are known and described, for example, in U.S. Pat. No. 4,327,177, incorporated herein by reference.
- the concentrator and methods of the invention can be used for protein selection or separation.
- the proteins can be growth factors, differentiation factors, chemotactic factors, or adhesion molecules. Proteins from the following general classes can also be used with the methods of the invention: prealbumins (thyroxine- and retinol-binding proteins), albumins, ⁇ - and ⁇ -globulins, apolipoproteins, coagulation proteins, cell-related plasma proteins, immunoglobulins, amyloid proteins and the like.
- prealbumins thyroxine- and retinol-binding proteins
- albumins thyroxine- and retinol-binding proteins
- albumins ⁇ - and ⁇ -globulins
- apolipoproteins apolipoproteins
- coagulation proteins cell-related plasma proteins
- immunoglobulins amyloid proteins and the like.
- the basic methodology for protein selection and collection involves centrifuging or other gravity separation of a biological fluid or disrupted cells or tissue.
- the height or window of the column which contains the specific desired protein can be infinitely adjusted to select the desired protein and collect the fluid.
- various filters can be used to further hone the concentration or concentrate specific proteins. This method of selection and collection helps to maintain protein viability and activity by maintaining their environment in the natural fluid.
- the proteins can be used, for example, for healing, surgical applications, therapeutic applications, tissue or cell culture, diagnostic purposes, or reapplied into a patient's body.
- one of more growth factors, one or more differentiation factors, one or more chemotactic factors, one or more adhesion molecules, or a combination thereof is administered to bone, cartilage, a wound, soft tissue injury, or surgical site to promote healing.
- the concentrated proteins can also be mixed with stem cells.
- the cartilage can be wounded, damaged, or severed.
- the wound can be a surgical incision, abrasion, ulcer, burn, or any other break in the skin.
- one of more growth factors, one or more differentiation factors, one or more chemotactic factors, one or more adhesion molecules, or a combination thereof is administered to a subject to treat an orthopedic disorder or during or after a surgical procedure to correct an orthopedic disorder to promote healing.
- the concentrated proteins can also be administered with stem cells.
- the concentrated proteins and/or stem cells are administered to the surgical site.
- the orthopedic disorder comprises spinal fusion, spinal defect, bone trauma, bone cyst, bone tumor, bone fracture, filling of osseous defect, joint augmentation, sinus augmentation, ridge preservation, joint revision, or posterolateral fusion.
- fluid or tissue from the kidney can be autologously concentrated in a device of the invention to obtain concentrated specimens of or fractions containing erythropoietin, urodilatin, calcitrol, and/or rennin.
- Fluid or tissue from the spleen can be autologously concentrated to obtain concentrated specimens of or fractions containing opsonins, properdin, and tuftsin.
- Fluid or tissue from the liver can be autologously concentrated to obtain concentrated specimens of or fractions containing bile, hepatocytes, cholangiocytes, unipotential or bipotential stem cells, insulin-like growth factor (IGF); angiotensinogen, and/or thrombopoietin.
- IGF insulin-like growth factor
- Fluid or tissue from the thyroid can be autologously concentrated to obtain concentrated specimens of or fractions containing hormones, principally thyroxine (T 4 ), triiodothyronine (T 3 ) and/or calcitonin.
- Fluid or tissue from the hypothalamus can be autologously concentrated to obtain concentrated specimens of or fractions containing corticotropin-releasing hormone (CRH), dopamine, gonadotropin-releasing hormone (GnRH), growth hormone releasing hormone (GHRH), somatostatin thyrotropin-releasing hormone (TRH), and/or hypocretin.
- Fluid or tissue from the pineal gland can be autologously concentrated to obtain concentrated specimens of or fractions containing melatonin.
- Fluid or tissue from the pituitary gland can be autologously concentrated to obtain concentrated specimens of or fractions containing TRH (thyrotropin-releasing hormone), CRH (corticotropin-releasing hormone), DA (dopamine, “prolactin inhibiting factor”/PIF), GnRH (gonadotropin-releasing hormone), GHRH (growth hormone releasing hormone), prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, endorphins and/or growth hormones.
- Fluid or tissue from the parathyroid can be autologously concentrated to obtain concentrated specimens of or fractions containing Parathyroid hormone (PTH).
- PTH Parathyroid hormone
- Fluid or tissue from the heart can be autologously concentrated to obtain concentrated specimens of or fractions containing atrial natriuretic peptide.
- Fluid or tissue from the stomach and/or intestines can be autologously concentrated to obtain concentrated specimens of or fractions containing cholecystokinin (CCK), gastrin, ghrelin, neuropeptide, secretin and/or somatostatin.
- Fluid or tissue from the pancreas can be autologously concentrated to obtain concentrated specimens of or fractions containing insulin, glucagons, somatostatin, pancreatic polypeptide, paracrine, autocrine and/or other hormones produced in the Islets of Langerhans.
- Fluid or tissue from the adrenal glands can be autologously concentrated to obtain concentrated specimens of or fractions containing glucocorticoids (cortisol), mineralocorticoids (aldosternone), and/or androgens (DHEA & testosterone). Fluid or tissue from the testes can be autologously concentrated to obtain concentrated specimens of or fractions containing androgens and/or testosterone. Fluid or tissue from the ovary can be autologously concentrated to obtain concentrated specimens of or fractions estrogens (estradiol) and/or progesterone. Fluid or tissue from the placenta can be autologously concentrated to obtain concentrated specimens of or fractions containing progesterone, estrogens, human chorionic gonadotropin, and/or human placental lactogen. Fluid or tissue from the thalamus or other portions of the endocrine system can be similarly autologously concentrated.
- cortisol glucocorticoids
- mineralocorticoids aldosternone
- DHEA & testosterone androgen
- the concentrator and methods of the invention can be used for isolation and purification of DNA.
- the DNA can be genomic DNA, plasmid DNA, DNA isolated from tissues or cells, synthetic oligonucleotides, and the like.
- the basic methodology for DNA isolation and purification involves disrupting the DNA-containing cells or tissue by chemical or mechanical means. The disrupted cells or tissue are then filtered using the filter element and then centrifuged in the concentrator of the invention. The cell or tissue layer is retained on the filter element, while the application of pressure allows the DNA-containing fluid layer to pass through the filter and into the centrifuge chamber of the concentrator device. Centrifugation can be performed on the ultracentrifuge or microcentrifuge scale, at high speeds of up to 15,000 RPM.
- the filter element of the invention can be an affinity column on which DNA in a fluid is preferentially adsorbed and then eluted.
- the methods of the invention allow DNA to be purified in a simple and efficient manner, with minimal mechanical or chemical manipulation. Purified DNA obtained by the methods of the invention can be used for a variety of diagnostic and therapeutic purposes.
- a concentrated fluid such as PRP and/or PPP
- a hemostasis gauze or pad can be applied to a hemostasis gauze or pad.
- the gauze or pad may be formed of a woven gauze material or a non-woven bandage material.
- the gauze or pad is preferably formed of a bioabsorbable material.
- a non-woven bandage material may be filled with autologous concentrated PRP.
- the hemostasis gauze or pad is applied to a wound site.
- the hemostasis gauze or pad can be directly applied to a site of bleeding to initially stop the bleeding, such as a vascular access sites after removal of a percutaneous catheter or tube, and then to accelerate tissue healing as the gauze or pad is bioabsorbed.
- the hemostasis gauze or pad can be coated with or contain other known hemostasis agents.
- concentrated PRP and/or PPP may be applied to a CHITO-SEAL topical hemostasis pad available from Abbott Vascular of Santa Clara, Calif., which is a soft, sterile, non-woven pad coated with chitosan. Chitosan is produced commercially by deacetylation of chitin (can be produced from chitin also), which is the structural element in the exoskeleton of crustaceans (crabs, shrimp, etc.).
- the concentrated PRP and/or PPP may also be applied to a pad containing thrombin separated from bovine plasma to enhance the hemostasis properties of the pad.
- thrombin-containing pads are available from Vascular Solutions of Minneapolis, Minn. as D-STAT DRY, D-STAT RADIAL, THROMBIGEL, D-STAT 2DRY and THROMBIX.
- Concentrated PRP and/or PPP obtained as described above can be used in flow hemostasis.
- the concentrated PRP or PPP can be autologous.
- Concentrated PRP and/or PPP can be applied directly in liquid form to the surface of a wound site.
- the concentrated PRP and/or PPP aids in inhibiting active bleeding from the wound by initiating the body's own clotting mechanisms.
- autologous concentrated PRP and/or PPP is combined with other presourced procoagulent components, such as collagen and thrombin.
- the concentrated PRP and/or PPP can be used to stop any active surface bleeding, and is particularly useful for direct application to radial artery access sites, to dialysis graft punctures following de-clotting procedures, to PICC/in-dwelling intravenous lines, and following arterial and venous sheath removal.
- Concentrated PPP obtained as described above can be applied directly in liquid form to the surface of a wound site.
- the autologous concentrated PPP helps to stop active bleeding from the wound by initiating the body's own clotting mechanisms.
- the autologous concentrated PPP may be combined with other presourced procoagulent components such as collagen and thrombin.
- the autologous concentrated PPP can be used to stop any active surface bleeding, and is particularly considered for direct application to radial artery access sites, to dialysis graft punctures following de-clotting procedures, to PICC/in-dwelling intravenous lines, and following arterial and venous sheath removal.
- the concentrated fluid of the invention is a combination of PRP and PPP.
- the concentrated fluid can be autologous.
- a concentrator of the invention is used to obtain concentrated platelet rich and concentrated platelet poor plasma from a sample of patient blood during surgery. Whole blood is withdrawn from the patient, and centrifuged in the '142 concentrator for 5 to 30 minutes at 25 to 10000 g, and most preferably for about 15 minutes at 4000 g. The central layers of platelet rich plasma and platelet poor plasma of the centrifuged blood are visually identified by color and withdrawn from the centrifuge chamber. Both layers are simultaneously passed through the filter unit under syringe pressure for one to ten passes, and most preferably 6 passes. The filtration can be tangential flow or dead end.
- tangential flow filtration using hollow polysulfone filter fiber membranes with a size cutoff of 0.1 nm to 100,000 nm and a surface area of 1 cm squared to 6000 cm squared is utilized.
- the filtration results in concentrated platelet rich/platelet poor plasma (“PRP+PPP”).
- the concentrated PRP+PPP obtained is a viscous liquid having increased concentrations of platelets, white blood cells, fibrinogen, thrombin, clotting factors and associated proteins and structures as compared to whole blood.
- Various known diluents, such as buffered saline can be used to adjust the viscosity of the autologous concentrated PRP+PPP for various applications.
- the resultant concentrated PRP+PPP product can be applied during surgery directly to a bone which has been fractured or damaged.
- the concentrated PRP+PPP produces benefits both of reduced bleeding at the fracture site followed by increased bone growth rates.
- the concentrated PRP+PPP is mixed with a bone void fillers, such as demineralized bone matrix (“DBM”).
- a bone void filler such as demineralized bone matrix (“DBM”).
- DBM demineralized bone matrix
- the resultant mixture is applied during surgery in any of numerous applications, including but not limited to spinal fusion, spinal defects, trauma, bone cysts, bone tumors, fracture management, filling of osseous defects, augmenting total joints, sinus augmentation, ridge preservation, joint revisions, posterolateral fusion procedures and general orthopedics applications.
- DBM demineralized bone matrix
- the concentrated PRP+PPP is applied as a cartilaginous repair material directly to a cartilage defect.
- the concentrated PRP+PPP can be mixed with chondrocytes obtained from a different source.
- the chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage of skeletally mature bovines with pronase and collagenase.
- the concentrated PRP+PPP is applied to an organ or tissue during transplanting, resulting in reduced bleeding followed by better acceptance of the new organ or tissue from the recipient's immune system and a lower chance of rejection.
- concentrated PRP+PPP is used as a surgical glue material. Either by itself or mixed with other surgical glue materials, the resultant concentrated PRP+PPP is used similar to surgical glue to adhere two tissue portions together.
Abstract
Description
- This application is being filed on 20 Jun. 2008, as a PCT International Patent application in the name of MILLENNIUM MEDICAL TECHNOLOGIES, INC., a U.S. national corporation, applicant for the designation of all countries except the U.S., and Matthew R. KYLE, a citizen of the U.S., and Thomas COULL, a citizen of the U.S., applicants for the designation of the U.S. only, and claims priority to U.S. Provisional Patent Application Ser. No. 60/945,733 filed on 22 Jun. 2007.
- The present invention is directed to devices and methods for concentrating fluids. More particularly, the present invention is directed to devices and methods for concentrating autologous biological or body fluids.
- Concentration and/or filtration of body fluids have long been practiced in the medical arts. Many medical treatments involve applying a fluid or gel-like substance to a wound or disease location. For some medical treatments, the fluid or gel-like substance is obtained from a body fluid of another person or animal. Body fluids, components of body fluids, or components of other body parts, such as tissue, may also be obtained from other species and used on human patients. Examples of such biological materials which are commonly used in current medical applications on humans are components of mammalian blood and bone, such as allogenic, xenogenic or autogenic graft materials, including from human, bovine and porcine sources. In some applications, the filtration and/or concentration process is carried out in an ongoing, streaming process, wherein the body fluid is simultaneously removed from the patient's body and then downstream returned to the patient's body. In other applications, the filtration and/or concentration process is carried out in a batch process, wherein an amount of the body fluid is removed from the body as a unit, treated, and then returned to the patient's body as a unit.
- More recently, body fluids such as blood fractions separated by centrifugation have been further filtered to increase cell or component concentrations in the filtrate. U.S. Pat. Nos. 5,733,545, 6,010,627 and 6,342,157 show examples of this, and are incorporated by reference. Such concentrated, centrifuged body fluids have been shown to be useful in various treatment modalities, such as applying the concentrated blood component directed to an orthopedic wound site. However, the methods and devices taught in the above patents have shortcomings which have prevented widespread acceptance and use in an operating environment. For example, the fluid or gel-like substance obtained from a body fluid of another person or animal is used in treatment and when applied to a patient, increases the risk for infection or diseases such as hepatitis or AIDS. The use of autologous body fluids avoids the risk of contracting a disease from external body fluids. When body fluids or components of body fluids are obtained from other species for use in human treatment, adverse reactions such as allergies, rejection, etc. can occur. The use of autologous body fluids also avoids the risk of rejection and other adverse reactions to fluids or tissue from an outside source.
- Therefore, there is a need for devices and methods for concentrating and/or filtering body fluids or autologous fluids in an efficient manner that prevents contamination of the fluids and allows the fluids to be used in treatment procedures where the risk of contamination, infection, or rejection remains high.
- In an aspect, the present invention includes an apparatus and method for concentrating a fluid, particularly an autologous fluid, for treatment of a patient. The concentrator apparatus includes a main housing defining a gravitational separation chamber, a filter housing containing a filter comprising a filter element, a piping for moving concentrated fluid from the separation chamber to the filter housing, and ports for pressurizing the concentrated fluid past the filter element of the filter. In am embodiment, the gravitational separation chamber is a centrifuge chamber.
- In another aspect, the present invention involves the creation and use of concentrated body fluids. A body fluid or tissue is extracted from a patient. The extracted substance is separated into different gravitational fractions, such as by centrifuge separation, gravitational weight separation or by mixing the extracted substance with a reagent that causes separation and/or precipitation. Once separated into different fractions, a portion of the column height is extracted, and then passed through a filter. The resultant concentrated, filtered product is then applied to a particular location with the same patient who provided the initial body fluid or tissue, or in a different patient. Depending upon which fraction is concentrated and filtered from which body fluid, the present invention can be used to treat a variety of conditions.
- In a third aspect, the concentrated autologous fluids are used in graft applications, including allograft, xenograft and autograft applications. The concentrated autologous fluids can be used to reconstitute freeze-dried or powdered allograft, autograft or xenograft materials. The concentrated fluids may also be applied directly to allografts or autografts during implantation, growth factors in the concentrated fluid promoting healing and tissue regeneration after implant surgery. The concentrated fluids may be coated onto an allograft material that then binds and/or interacts with reactive functional groups coated onto a polymer core, allowing the allograft to release growth factors in a controlled manner over the period of time required for healing after surgery.
-
FIG. 1 is a perspective view of a first embodiment of the invention. -
FIG. 2 is a cross-sectional side view of the embodiment ofFIG. 1 taken along lines 2-2. -
FIG. 3 is a cross-sectional side view of the embodiment ofFIG. 1 taken along lines 3-3. -
FIG. 4 is a cross-sectional plan view taken along line 4-4 inFIGS. 2 and 3 . -
FIG. 5 is a side view ofFIGS. 2 and 3 , simplified and modified so as to show all functions on a single view, with arrows A-I indicating the stepwise handling of the body fluid through the inventive device. -
FIG. 6 is a cross sectional side view of a second embodiment of the invention. -
FIG. 7 is a perspective view of a third embodiment of the invention, showing hidden detail in dashed lines. -
FIG. 8 is a cross-sectional view of the embodiment ofFIG. 7 . - While the above-identified drawing figures set forth preferred embodiments, other embodiments of the present invention are also contemplated, some of which are noted in the discussion. In all cases, this disclosure presents the illustrated embodiments of the present invention by way of representation and not limitation. Numerous other minor modifications and embodiments can be devised by those skilled in the art which fall within the scope and spirit of the principles of this invention.
- Various embodiments of the present invention will be described in detail with reference to the drawings, wherein like reference numerals represent like parts throughout the several views. Reference to various embodiments does not limit the scope of the invention, which is limited only by the scope of the claims attached hereto. Additionally, any examples set forth in this specification are not intended to be limiting and merely set forth some of the many possible embodiments for the claimed invention.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art. Although any methods, devices and material similar or equivalent to those described herein can be used in practice or testing, the methods, devices and materials are now described.
- The term “body fluid” refers to a biological fluid collected from a subject. The subject can be a mammal, including but not limited to human, bovine, pig, sheep, horse, or goat. The body fluids can be autologous. Body fluids include, but are not limited to, blood, plasma, serum, urine, saliva, mucus, cerebrospinal fluid, lymphatic fluid, seminal fluid, amniotic fluid, vitreous fluid, as well as fluid collected from cell culture of patient cells, and the like. Body fluids also include tissue such as, for example, bone, bone marrow, muscle tissue, brain, heart, liver, lung, stomach, small intestine, large intestine, colon, uterus ovary, testis, cartilage, soft tissue, skin, subcutaneous tissue, breast tissue, tissue obtained from other species, patient tissue from surgery, and the like. The tissue can be disrupted. Methods for disrupting tissue are known and include homogenization and enzymatic treatments. The body fluids of the invention also include, for example, bone marrow, fluids obtained from surgery, fluid filtrates, tissue filtrates or fragments, bone chips or fragments obtained during surgery, and the like.
- The term “concentrated” refers to a fluid which has been separated by gravity, centrifugation, and/or filtration into various fractions. The term fraction refers to the various components into which a biological fluid can be separated by centrifugation, gravitational weight separation and/or filtration. Each fraction is richer in a particular fluid component (i.e. concentrated) relative to the other fraction and the original fluid. The concentration process also removes nonessential components such that the concentrated fraction contains only necessary or desired components.
- “Allograft” as used herein refers to a tissue or organ obtained from one patient and grafted to a genetically dissimilar patient. When the tissue or organ is obtained from one part of the patient's body and is grafted to another part of the same patient's body, the material is an autograft. Allograft materials include, without limitation, bone, bone powder, bone chips, or bone particles, tendons, ligaments, skin, lens fragments, and the like, obtained from mammalian sources, including bovine, porcine and human sources. Human sources include patients and cadavers. Allograft materials are usually freeze-dried and must be reconstituted in a biocompatible fluid prior to use. Allograft materials may also be substituted with biosynthetic and synthetic materials including, without limitation, demineralized bone matrix, collagen, ceramics, cements, polymers and copolymers.
- The term “growth factor” as used herein means a bioactive molecule that promotes proliferation of a cell or tissue. Growth factors useful in the present invention include, but are not limited to, transforming growth factor-alpha (TGF-alpha), transforming growth factor-beta (TGF-beta), platelet-derived growth factors including the AA, AB and BB isoforms (PDGF), fibroblast growth factors (FGF), including FGF
acidic isoforms 1 and 2, FGFbasic form 2, andFGF - The term “differentiation factor” as used herein means a bioactive molecule that promotes differentiation of cells or tissue. The term includes, but is not limited to, neurotrophin, colony stimulating factor (CSF), or transforming growth factor. CSF includes granulocyte-CSF, macrophage-CSF, granulocyte-macrophage-CSF, erythropoietin, and IL-3. Some differentiation factors can also promote growth or proliferation of a cell or tissue. TGF and IL-3, for example, can promote differentiation and/or growth of cells.
- “Chemotactic factors” refers to a bioactive molecule responsible for regulating the movement of essential chemicals necessary for proper development, healing and/or homeostasis of cells and tissues. Chemotactic factors include cytokines. Cytokines include, but are not limited to, cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5, interleukin (IL) 1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF-alpha, and TNF-beta.
- The term “adhesion molecule” refers to bioactive molecules that promote or facilitate adhesion with other cells or with the extracellular matrix (ECM) or basement membrane (BM). Adhesive proteins include actin, fibrin, fibrinogen, fibronectin, vitronectin, laminin, cadherins, selectins,
intracellular adhesion molecules - As used herein, the terms “treatment” and “treating” refer to the process of administering or applying a concentrated biological fluid or concentrated body fluid to a patient at the site of a wound or injury in order to cause or promote healing at the wound or injury site. The concentrated fluid can be autologous. The concentrated fluid or concentrated body fluid is applied in a therapeutically effective amount. For example, an amount sufficient to cause wound or injury healing when an autologous fluid is applied to a wound or injury site would be a therapeutically effective amount.
- The present invention is directed to concentration of body fluids using a concentrator device, and uses of concentrated body fluids and similar substances produced using the concentrator device. Concentrated body fluids obtained by the methods of the present invention having many uses, including treatment of a variety of medical conditions.
- A. Fluid Concentrator
- The present invention includes a fluid concentrator device for concentrating body fluids. The body fluids can be autologous body fluids. The
concentrator 10 of the present invention primarily includes amain housing 12 which definesseparation chamber 14. For ease of manufacture and assembly, themain housing 12 may be formed as abase plate 16, acentral housing 18, and atop plate 20 as shown inFIG. 1 . Themain housing 12 is preferably molded of plastic, but could be formed of any sterilizable material. As part of manufacture and assembly, thebase plate 16,central housing 18 andtop plate 20 are preferably sealed to each other, such as through an epoxy sealant or sonic welding. Thebase plate 16,central housing 18 andtop plate 20 may alternative be formed with mating threads so as to screw together, and sealed such as with a common O-ring. - An embodiment, the
central housing 18 is transparent or semi-transparent, thereby allowing viewing of the fluid contained within thecentrifugation chamber 14 of thecentral housing 18. This allows viewing of the body fluid after separation, to better determine which fraction of the fluid to remove from theseparation chamber 14. Alternatively, thecentral housing 18 may include a window, i.e., a portion which is transparent or semi-transparent. When a biological fluid or body fluid is placed into thechamber 14 and centrifuged, color distinctions between the various components or fractions can be visually discerned. For example, where the body fluid is blood, platelet poor plasma, buffy coat and red blood cell fractions or components have distinct colors and can be visually distinguished from one another. For fluids which do not visually separate during centrifugation or gravitational separation weight, or if a float or other mechanism is used to determine which portion of the separated fluid to remove from theseparation chamber 14, no window is necessary. - In an embodiment, the overall size of the
main housing 12 is selected to be compatible with existing centrifuges. For example, centrifuges are presently available which handle 4×4 inch vessels, and themain housing 12 is dimensioned to mate with and be received by the common 4×4 inch centrifuge (not shown). In an embodiment, themain housing 12 is dimensioned to mate with and be received by a 8×8 inch centrifuge. In an embodiment, themain housing 12 is dimensioned to mate with and be received by a 12×12 inch centrifuge. In an embodiment, themain housing 12 is dimensioned to mate with and be received by up to a 40×40 inch centrifuge, such as for small volumes up to 250 μL. Thebottom wall 22 of thebase plate 16 is flat and includes no ports or items projecting from it, so the concentrator 10 can stand on a flat surface and will be stable during centrifugation. - The
top plate 20 includes anopening 24 which serves as a fluid inlet. Theinlet 24 preferably includes a closure mechanism 26 (shown schematically inFIG. 3 ). Theclosure mechanism 26 could be a rubber stopper, with the fluid hypodermically injected through the rubber stopper into theseparation chamber 14. However, thepreferred closure mechanism 26 is a cap with a hand-turnable luer lock, commonly known in the fluid handling art. - As shown in
FIG. 1 , a valve adjustment handle 28 is accessible in thetop plate 20, and a valve control handle 30 is accessible in thebase plate 16. These twohandles valve inlet 32 and valve 34 (shown inFIG. 2 ) which are located within theconcentrator 10. The valve adjustment handle 28 allows hand rotation of a threadedvalve opening stem 36, the rotation of which changes the height of thevalve inlet 32 relative to themain housing 12. As best shown inFIG. 2 , the valve adjustment handle 28 is used to position thevalve inlet 32 at a desired height to correspond with the height of the desired fluid layer after separation. Thevalve inlet 32 thus serves as the outlet port to remove a fraction of fluid from theseparation chamber 14. While a threadedstem 36 provides an easy way of adjusting the height of thevalve inlet 32, many equivalent mechanisms could be used such as a slide, float or other adjustment feature. - As shown in
FIG. 2 , afilter unit 38 is disposed within theseparation chamber 14. Thefilter unit 38 connects between abase port 40 defined in thebase plate 16 and atop port 42 defined in thetop plate 20.Piping 44 is included to transport the fluid from thevalve inlet 32 to thebase port 40 or inlet to thefilter unit 38. - As best shown in
FIGS. 2-4 , thepreferred filter 46 includes afilter housing 48 and a filter element, or membrane. The filter element of the present invention comprises a material capable of acting as a separation medium, a filtration medium, or a growth matrix or surface. Separation and/or filtration media include affinity columns, packed bed matrices and beads. Nanofiber networks can be used as filtration media or growth matrix or growth surface. Nanofiber networks and methods of making nanofiber networks are known and commercially available from Surmodics (Minneapolis, Minn.). See, for example, WO 2006/094076, U.S. 2005/0095695 and U.S. 2007/0082393, incorporated herein by reference. In embodiments, the filter element comprises a reaction chamber or holding chamber to collect and retain separated fraction and/or filtered fluids or cells. - In embodiments, the filter element or membrane comprises an affinity membrane, support or column. Affinity columns used in chromatographic separation or purification of proteins and other biological macromolecules make use of specific binding interactions between molecules. In an aspect, a particular ligand is chemically immobilized or “coupled” to a solid support. Ligands that bind to general classes of proteins (such as, for example, receptors or antibodies) or commonly used fusion protein tags (such as, 6×His) are commercially available in pre-immobilized forms ready to use for affinity purification. Alternatively, more specialized ligands such as specific antibodies, antigens or receptors of interest can be immobilized using one of several commercially available activated affinity supports. For example, a peptide antigen can be immobilized to a support and used to purify antibodies that recognize the peptide. Similarly, a receptor that binds a growth factor, differentiation factor, chemotactic factor, or adhesion molecule can be immobilized to a support and used to purify said factors or molecules in the concentrated fraction of body fluids. Antibodies and receptors that bind growth factors, differentiation factors, chemotactic factors, or and/or adhesion molecules methods of making such antibodies and receptors, and methods of immobilizing the antibodies and receptors on a support are known.
- One or more ligands can be attached to a filter element of the invention. The ligands can be selected to bind one or more particular growth factors, differentiation factors, chemotactic factors, and/or adhesion molecules. The ability to attach one or more selected ligands to a filter element of the invention provides for the creation of a custom concentrated body fluid, wherein the particular bioactive molecules comprising the concentrated body fluid are defined, for example, by the particular ligands, concentration of ligands, and/or ratio of one ligand to another selected by the user.
- Most commonly, ligands are immobilized or “coupled” directly to a solid support material by formation of covalent chemical bonds between particular functional groups on the ligand and reactive groups on the support. Examples of functional groups and reactive groups include, without limitation, primary amines, sulfhydryls, carboxylic acids, aldehydes, and the like. However, other coupling approaches are also possible. For example, a GST-tagged fusion protein can be first bound to an immobilized glutathione support by affinity interaction with the GST tag and then chemically cross-linked to the support. The immobilized GST-tagged fusion protein can then be used to affinity purify its binding partner(s).
- In embodiments, the filter element or membrane comprises affinity or chromatography beads or particles. The beads or particles can be, for example, glass, alginate, polymeric, or magnetic beads or particles. The beads or particles function in the same way as affinity matrices or columns, but are significantly reduced in size, and are therefore particularly useful for microscale biological manipulations. In embodiments, an affinity column or affinity bead or particle is used as the filtration element of the concentrator device such that when a separated fluid or fluid fraction fluid is passed over the beads or particles, those molecules or fluid components that have specific binding affinity to the ligand are retained on the beads, and can be retrieved or isolated by subsequent elution.
- In embodiments, the filter element or membrane comprises a packed bed matrix or column. A packed bed is a bed of granular material which retains the solid particles as it passes, allowing fluids and liquids to be filtered free of solid contaminants or components. In an aspect, the granular material for the packed bed can be sand, although celite or diatomaceous earth packed in a microscale container or loaded on top of a sintered-glass funnel can also serve as the packed bed. Incompressible diatomaceous earth (i.e. primarily silica), wood cellulose or other inert porous solids can also be used as the granular material of the packed bed filter. In embodiments, a packed bed matrix or column is used as the filtration element of the concentrator device such that when the separated fluid or fluid fraction is passed over the column, solid components or fluid components with a size greater than the pore size of the packed bed material are retained on the packed bed, while other fluid components pass through.
- In embodiments, the filter element or membrane comprises a network of one or more nanofibers, a nanofibrillar structure, glass, silicon, or plastic comprising an etched or micropatterned surface, glass, silicon, or plastic surface comprising macropores or nanopores, or a polymer scaffold. Nanofiber networks of this type are described in WO 2006/094076, U.S. 20050059695, and U.S. 20070082393, incorporated herein by reference. The nanofiber network can be deposited on a surface of a substrate, and the combination of the nanofiber on the substrate can be a growth matrix or substrate, or as a filtration membrane. In an embodiment, the nanofiber network comprises a fiber diameter of about 30 nm to about 1200 nm, average interfiber spacing of about 100 nm to about 600 nm, and solidity of about 70 percent or less. The nanofibers can be fabricated from a variety of polymers or polymer systems. Preferably the polymer or polymer system is non-cytotoxic. In an embodiment, the nanofibers are fabricated from a polyamide or polyester. The polyamide can be nylon 6,
nylon 66, nylon 610 or other biocompatible polyamides. The polyester can be poly(c-caprolactone), poly(lactate) or poly(glycolate). In an embodiment, the polyamide or polyester is suitable for in vivo human application. - The filter element or membrane can also be a nanofibrillar structure comprising one or more nanofibers. The network of one or more nanofibers, as described above, defines the nanofibrillar structure. In an embodiment, the nanofiber network is deposited on a surface of a substrate to provide a growth matrix or surface. In some embodiments, the substrate can be glass, polymeric, metallic, ceramic, cellulosic, or proteinaceous. Examples of a substrate include but are not limited to a rod, screw, wire, mesh, or cage. The substrate can be a surface of a culture container, coverslip, or film. The film can be water soluble or water insoluble, biodegradable or biodissolvable. Preferably the film is non-cytotoxic. In an embodiment, the film comprises polyvinyl alcohol, polychlorotrifluoroethylene, polystyrene, polymethylpentene, or polycylo-olefin. The nanofibrillar structure can be utilized singly or layered to form a multi-layered assembly of nanofibrillar structures for cell or tissue culture. In an embodiment, the nanofibrillar structure comprises a spacer. The spacer can function as a support structure. The spacer provides sufficient openings to permit cells to penetrate and attach to the nanofiber network. The spacer can be water soluble or water insoluble, porous or non-porous, biodegradable or biodissolvable. Preferably the spacer is biocompatible. In embodiments, the nanofibrillar structure is used as a filter element or membrane of the concentrator device, such that when the separated fluid or fluid fraction is passed over the filter element, solid components or fluid components with a size greater than the pore size of the nanofibrillar material are retained on the material, while other fluid components pass through. In other embodiments, the nanofibrillar structure can be a growth matrix, such that when the centrifuged autologous fluid is passed over the filter element, growth factors in the fluid are retained on the element and can be used to support subsequent cell or tissue growth.
- In some embodiments, the separation chamber is configured to accept a filter element or membrane of the invention. In such configuration, the filter element or membrane can act as a prefilter to remove unwanted particles or macromolecules from the body fluid prior to separation or during the separation process. In an embodiment, affinity beads or particles that bind a specific molecule, less of molecules, or particular combination of molecules can be used to remove unwanted particles or macromolecules from a fluid. The beads or particles can be added to a biological fluid or body fluid in the separation chamber or the beads or particles can be added to the separation chamber prior to adding the biological fluid or body fluid to the separation chamber. The beads can be removed before or after separation. In an embodiment, a reagent can be added to the separation chamber or biological or body fluid to precipitate out particles or macromolecules. In an embodiment the reagent is an antibody or soluble receptor.
- In some embodiments, the filter element or membrane of the invention is not tolerant to centrifugation. In such instances, the filter element or membrane is removed from the
filter housing 48 and reinstalled into thefilter housing 48 after centrifugation. - In an embodiment, the filter membrane has a large number of longitudinally oriented stranded
filter lumens 50. Thefilter strands 50 are sealed withseals 52 to thefilter housing 48 at each end. Thepreferred filter strands 50 are about 3½ inches long, with hundreds offilter strands 50 placed within a ¾ inchdiameter filter housing 48, to provide a filter area of about 800 cm2 or more. Thefilter strands 50 preferably have a pass size of about 10 to 30 kDalton through the lumen wall. With thesefilter strands 50, the filtrate or retentate moves longitudinally through thelumens 50 and through thefilter housing 48, while water and low molecular weight components (generically called “permeate”) pass through thefilter membrane 50 transverse to the filter flow direction. Filter strands such as this may be available, for example, from Spectrum Labs of Rancho Dominguez, Calif. or Minntech of Plymouth, Minn. - In an embodiment, if desired, the
base port 40 and thetop port 42 may include female threads (not shown) to receivetransfer syringes FIG. 5 . Thetransfer syringes filter 46. If desired, thebase port 40 and thetop port 42 may be recessed to allow thetransfer syringes filter 46, thereby minimizing the piping distance (and piping volume) from thetransfer syringes filter 46. - In alternate embodiments, the
transfer syringes transfer syringes - In an embodiment, the
base port 40 and thetop port 42 are disposed on the side of theconcentrator 10, oriented transverse to thelongitudinal axis 58. This placement allows thebase port 40 to be accessible while theconcentrator 10 is standing upright on thebottom wall 22 of thebase plate 16, and allows thetop port 42 to help balance thebase port 40 during transfer of the fluid component through thefilter 46. Alternatively, thebase port 40 and thetop port 42 could be slanted relative to thelongitudinal axis 58, or even extend through thebottom wall 22 of thebase plate 16 andtop wall 60 of thetop plate 20 parallel to thelongitudinal axis 58. Placement of theports longitudinal axis 58 would align the syringe plunger strokes with the direction of fluid movement through thefilter 46, thereby reducing the pressure loss due to piping turns and thereby reducing the risk of damaging the fluid during use of theconcentrator 10. - As shown in
FIGS. 3-5 , avacuum port 62 connects through themain housing 12 and through thefilter housing 48. With thevacuum port 62, vacuum pressure 64 (shown schematically inFIG. 4 ) can be applied to the exterior of thefilter strands 50 while the blood component passes through thefilter lumens 50.Vacuum sources 64 are commonly available in environments where theconcentrator 10 is utilized. If novacuum source 64 is available, thevacuum port 62 still serves as a gravitational drain to remove water and low molecular weight components that have passed through thefilter membrane 50. To help vacuumport 62 act as a gravitational drain, it is placed at the bottom of thefilter chamber 66. - In an embodiment, the
filter housing 48 is sealed to eliminate fluid communication between theseparation chamber 14 and thefilter chamber 66. Alternatively, thefilter housing 48 may be open to theseparation chamber 14, such that the water and low molecular weight components which pass through thefilter membrane 50 proceed into theseparation chamber 14. If thefilter housing 48 permits fluid communication between thefilter chamber 66 and theseparation chamber 14, then thevacuum port 62 will serve to remove or drain the desired fluid fraction or component as well as water and other low molecular weight components from theconcentrator 10. - The use of the invention is described with respect to the lettered steps shown in
FIG. 5 . In an embodiment, a sample of body fluid (approximately 60 to 80 mL) is placed through theinlet closure 26 and into theseparation chamber 14 as shown by arrow A. Preferably, this occurs within minutes after the fluid is withdrawn from the patient. Different amounts or different types of fluid can be alternatively used if theconcentrator 10 is used for a different concentration purpose. - In an embodiment, once the entire fluid sample is within the
separation chamber 14, theinlet closure 26 is closed, and theconcentrator 10 is centrifuged. The centrifugation process is performed in accordance with known centrifuge strategies and velocities, as further described below. - After centrifugation or gravitational weight separation is complete, the fluid has separated into different layers, which may be visually discernable by viewing through the
central housing 18.Transfer syringes base port 40 and thetop port 42. The valve adjustment handle 28 is rotated until the height of thevalve inlet 32 lines up with the bottom of the fluid layer(s) desired to be further processed. Thevalve 34 is opened using the valve control handle 30, while the desired fluid layer(s) drain into thebase plate 16 and thebottom syringe 54 as shown by arrows B and C. If necessary for pressure relief to enable all of the desired fluid layers to be removed from theseparation chamber 14, theinlet closure 26 may be opened slightly during draining of the desired fluid layers through thevalve 34. Preferably, however, theinlet closure 26 will incorporate a valve (not shown) allowing for pressure release. Once the desired fluid layer(s) have been extracted, the valve control handle 30 is used to close off thevalve 34. The unwanted layers are retained in theseparation chamber 14. - Vacuum pressure is now applied to the
vacuum port 62. Because the remainder of the concentration procedure does not rely on gravitational weight separation, theconcentrator 10 device may be placed on its side if desired. Thevacuum port 62 is preferably located on a side of thecentral housing 18 opposite thetransfer ports 40; 42, thereby providing counterweight and stabilization during transfer of the desired fluid layer(s) through thefilter 46. Theplunger 68 on thebottom syringe 54 is pushed (while theplunger 68 on thetop syringe 56 is optionally being pulled), pushing the desired fluid upward and into thetop syringe 56 as shown by arrows D and E. Water, low molecular weight elements and any other unwanted components of the desired fluid are removed through thefilter strands 50, as shown by arrows F, and then drained through thevacuum port 62 as shown by arrow G. The desired fluid passes through thefilter strands 50 and into thetop syringe 56 as shown by arrow H, becoming “first pass concentrated”. - In an embodiment, the volume of the piping 44 from the
valve inlet 32 to thefilter 46, including thebottom syringe 54, is minimized so as to get as great a yield of concentrated desired fluid from a single starting sample as possible. If desired, thetop port 42 and thebase port 40 may include recesses to receive a greater length of thetransfer syringes transfer syringes filter housing 48. - The first pass concentrated fluid can be further concentrated by reverse filtering. The
plunger 68 on thetop syringe 56 is pushed (while theplunger 68 on thebottom syringe 54 is optionally pulled), thereby pushing the first-pass concentrated fluid through thefilter 46 as shown by arrow I and into thebottom syringe 54. Additional water and low molecular weight components are withdrawn from the first-pass concentrated fluid (arrows F and G). The reverse filtering makes additional use of the filter element ormembrane 50 and further concentrates the first pass concentrated fluid into “second pass concentrated” fluid. If desired, additional passes may be performed in a like manner. - The concentrated fluid may be used immediately or after further preparation such as mixing the concentrated fluid with other components, growth factors, differentiate factors, chemotactic factors, and/or adhesion factors suitable for use in various applications. For example, where blood is autologous fluid, the concentrated fluid is mixed with thrombin and then brushed it onto an implant's surface.
- In an embodiment, the stranded
filters 50 used are single use filter elements, which cannot be effectively cleaned and sterilized. Accordingly, thefilter element 46 is disposed of after its single use. In an embodiment, the entire separation/filtering vessel 10 is sufficiently inexpensive that theentire concentrator 10 unit can be discarded after a single use. This simplifies and/or avoids cleaning of the separation unit and/or filterhousing 48. This also simplifies disposal of the undesired fluid components. - Filtering within the separation vessel provides further advantages which can be achieved in alternative embodiments. For instance, if the
inlet 32 for thedrain valve 34 is automatically (rather than visually) positioned at the proper height for the desired fluid layer(s), then thedrain valve 34 could be automatically opened using centrifugally activated valves as known in the art. Using similar arrangements, the desired fluid layer(s) can be passed through thefilter 46 during centrifugation, using centrifugal forces to push/pull the desired fluid layer(s) through thefilter 46. - In an embodiment, the
filter 46 is oriented longitudinally with respect to the centrifugation direction (i.e., with respect to longitudinal axis 58). This helps minimize the possibility that thefilter strands 50 might pull from their end seals 52 and/or break during centrifugation. Alternative embodiments could include orienting thefilter strands 50 transversely and at the general height of the desired fluid layer(s), thereby further reducing the piping volume needed to transfer the desired fluid layer(s) to thefilter 46. - In an embodiment,
external syringes filter 46. This provides a low cost method of applying such forces. In an embodiment,syringes filtration chamber 66 to force a selected amount of water and low molecular weight components of the centrifuged fraction through thefilter membrane 50. As an alternative to the use of external syringes, thesyringes 54, 56 (including particularly theplunger 68 and slide tube elements 70) could be fabricated and/or attached as part of the device. For instance, thebottom wall 22 of thebase plate 16 and thetop wall 60 of thetop plate 20 could be slidable or depressible similar to the plunger on a syringe, to thereby apply the transfer pressure to push/pull the desired fluid layer(s) through thefilter 46. The use ofsyringes filter 46 to be hand controlled by the surgeon or other operator. - An additional embodiment of the invention is shown in the
concentrator 80 ofFIG. 6 . Similar to thefirst embodiment 10, the same vessel used in separation is also used to provide filtration. In an embodiment, fluid is centrifuged in theconcentrator vessel 80 or subjected to gravitational weight separation in theconcentration vessel 80, and then positive or negative pressure is applied in thesame concentrator vessel 80 after separation to force water, low molecular weight components, and other undesired components from the separated fraction resulting in a first pass concentrated component. - The
concentrator vessel 80 includes threechambers separation chamber 82 holds the fluid during separation. Awater chamber 84 receives water, low molecular weight components and other undesired components removed from the desired fluid layer(s) through thefilter 46. Aconcentrated fluid chamber 86 receives the concentrated fluid which has been filtered. - The
separation chamber 82 preferably holds afloat 88 of a particular specific gravity, such as generally equal to the specific gravity of buffy coat. Thefloat 88 can be used to aid in positioning of a syringe (not shown) during transfer of the desired fluid layer(s) from thecentrifuge chamber 82 to thefilter 46. Alternatively, openings in thefloat 88 can be provided to permit fluid fraction flow therethrough during centrifugation. - The “shut off”
valve 90 for theconcentrated fluid chamber 86 may be a variable position valve that would allow the operator to “dial in” the maximum pressure that could be generated in theconcentrated fluid chamber 86, and/or the maximum pressure differential between thewater chamber 84 and theconcentrated fluid chamber 86, thereby controlling the concentration of the final output. For example, the shut offvalve 90 may include a dial with three or more positions connected to something like a butterfly valve or regulator valve, such that the operator selects the desired concentration on the dial then pressurizes the desired fluid layer(s) through thefilter 46 to the selected pressure/concentration level. Depending on the dial position selected, a predetermined pressure is generated across thefilter 46 that allows for the corresponding amount of water to be removed, thus delivering the desired concentration in one stroke and without the need to fully close off theoutport 92. - In a third embodiment shown in
FIGS. 7 and 8 , a desired fluid layer(s)isolation chamber 94 is defined between theseparation chamber 14 and thefilter unit 38. Also, awindow valve 96 is added between theseparation chamber 14 and theisolation chamber 94. Thewindow valve 96 is ordinarily closed, preventing fluid communication between theseparation chamber 14 and theisolation chamber 94. Thus, while the starting fluid sample is in theseparation chamber 14 and during separation, there is no possibility of the starting fluid passing through thewindow valve 96 and into the isolation chamber 94 (or into other piping between theseparation chamber 14 and thefilter unit 38 such as piping 44 in the first embodiment). - In an embodiment, the
window valve 96 has alocking mechanism 98, which also acts as a valve handle. Alock 100 prevents thelock handle knob 102 from being pushed down, thereby preventing thewindows 104 from being pushed down into communication with theseparation 14 during separation, such as. Once separation is complete, thelock handle knob 102 is rotated 90° to a position where thelock 100 lines up with akeyway 106, enabling theknob 102 to be pushed downward against aspring 108. Thewindows 104 are attached to and controlled by theknob 102, and pushing thelock handle knob 102 downward moves thewindows 104 downward into communication with theseparation chamber 14. When thewindows 104 are open to theseparation chamber 14, the desired fluid layer(s) of the separated fluid flow by gravity from theseparation chamber 14 into theisolation chamber 94. Once the desired fluid layer(s) have drained into theisolation chamber 94, theknob 102 is released, with thespring 108 moving thewindows 104 upward and closing communication between theisolation chamber 94 and theseparation chamber 14. - The
isolation chamber 94 holds the desired fluid layer(s) until subsequent processing, such as filtration. Theisolation chamber 94 defines the volume of the desired fluid layer(s) which will be removed from the starting fluid unit and filtered. Placement of the desired fluid layer(s) within theisolation chamber 94 allows theconcentrator 10 to be handled without fear of remixing the desired fluid layer(s) into the remainder of the starting fluid. For example, after the desired fluid layers(s) are moved into the isolation chamber, theconcentrator 10 can be placed on its side prior to fluid filtration. Theisolation chamber 94 also permits a delay time between separation and filtering. The desired fluid layer(s) can optionally be further treated while in theisolation chamber 94. For example, additives may be mixed with the fluid within theisolation chamber 94, particularly if the additives enhance the filtration process, such as by having the additives in theisolation chamber 94 prior to opening thewindow valve 96. - A
twist valve 110 is opened to open communication between theisolation chamber 94 and thebase port 40 and thefilter unit 38. The desired fluid layer(s) are withdrawn from theisolation chamber 94 through thetwist valve 110 with asyringe 54, at which point thetwist valve 110 is closed. The plunger stroke on thesyringe 54 is then reversed to push the desired fluid layer(s) through thefilter unit 38. If desired, thesyringes filter unit 38 can have a much lower volume than the isolation chamber 94 (say, for instance, ⅓ the volume). Then fluid can be removed from theisolation chamber 94 in portions (⅓ at a time) which are filtered separately, one portion at a time. Portioning of the desired fluid layer(s) through thefilter unit 38 is particularly advantageous in situations wherein preparation steps are taken for thefilter 46 between portions. For instance, if thefilter 46 is becoming clogged while only filtering ⅓ of the fluid volume in theisolation chamber 94, a purge fluid could be pressured through thefilter 46 to unclog thefilter 46 prior to filtering the second portion through thefilter 46. After the first portion has been filtered and thefilter 46 purged, thetwist valve 110 is reopened to remove a second portion. Thetwist valve 110 is then reclosed to permit filtering of the second portion, followed by any purging of thefilter 46. Because thetwist valve 110 controls communication between theisolation chamber 94 and thebase port 40, fluid may thus be removed from theisolation chamber 94 in whatever size portions are desired. - In another embodiment (not shown), a syringe having a plunger is provided to pull (negative pressure) the component out of the centrifuged starting fluid (i.e. the original fluid sample). The syringe also houses a
filter 46, and the plunger stroke is reversed to push (positive pressure) the component through thefilter 46 and separate the component into water and a concentrated retentate. - In all these embodiments, the surgeon or other operator controls the pressure and/or duration of the filtration step, and thus the surgeon or other operator controls how concentrated the concentrated retentate is relative to the separated component, as well as how hard the fluid is worked during the filtration step.
- B. Protein Separation and Concentrated Autologous Fluids
- A concentrator device of the invention can be used to separate organelles, cells or proteins, in addition to concentrating body fluids. Separation can be performed by centrifugation or gravitational weight separation. In some embodiments, the body fluids may be autologous body fluids. Centrifugation is a process used to separate or concentrate materials suspended in a liquid medium. The theoretical basis of this technique is the effect of gravity on particles (including macromolecules) in suspension. Two particles of different masses will settle in a tube at different rates in response to gravity. Centrifugal force (g) is used to increase this settling rate, and the means to increase the rate is a centrifuge. The centrifugal force generated is proportional to the rotation rate of the rotor (in RPM) and the distance between the rotor center and the centrifuge tube. Therefore, a given centrifuge may use multiple rotor sizes to give flexibility in choosing centrifugation conditions.
- Rotors for centrifuge devices are either fixed angle, swinging bucket, continuous flow, or zonal, depending upon whether the sample is held at a given angle to the rotation plane, is allowed to swing out on a pivot and into the plane of rotation, designed with inlet and outlet ports for separation of large volumes, or a combination of these. In embodiments, the methods of the present invention use continuous flow centrifugation for separation and concentration of large fluid volumes. Continuous flow centrifugation can also be used for the large scale separation of particles on density gradients. These rotors can contain up to 2 L of fluid and can work with tissue samples measured in ounces. The rotors are brought up to about 3000 RPM while empty, and the density media and tissues are added through specialized ports. This type of rotor has a distinct preparative advantage over the gradient capacity of more typical rotors. In embodiments, the rotors are used in ultracentrifugation processes, and contain small volumes of fluid, up to 250 mL. The rotors can be used for laboratory manipulations where only small fluid volumes or tissue amounts are available. For ultracentrifugation, the rotors are brought up to 15,000-18,000 RPM with a maximum of 20,000 RPM. Rotors for standard centrifugation can range from 4 by 2 or 2.5 L to 40 by 250 μL. For ultracentrifugation applications, rotors can range from 6 by 250 mL to 72 by 230 μL, with wide intermediate ranges such as, for example, 8 by 6.8 mL, 6 by 94 mL, 6 by 4 mL, 8 by 5.1 mL, and 8 by 39 mL. The main housing of a fluid concentrator of the invention can be dimensioned to mate and be received by a standard centrifugation rotor or ultracentrifugation rotor. As with standard centrifugation, the rotors can be brought up to speed while empty, with the media, samples and tissues introduced through special ports.
- The concentrator of the invention can be used to separate proteins or cells by density gradient centrifugation. The use of density gradients is routine in centrifugal fractionation of particle mixtures, cells mixtures, and purification of subcellular organelles and macromolecules, including proteins. A particle can be a macromolecule or cell. The mixture of particles to be separated is placed onto the surface of a vertical column of liquid, the density of which progressively increases from top to bottom, and then centrifuged. Although the particles in suspension are individually denser than the liquid at the top of the gradient, the average density for the sample (i.e. particles plus suspending liquid) is lower. The two main types of density gradient centrifugation are rate-zonal separation and isopynic separation. In rate-zonal separation particles are separated based on their size and mass. The particles migrate through the gradient until they reach the point at which their size and mass match that of the gradient. This centrifugation method is useful in separating out particles with the same or very similar densities, but different masses. Many proteins, such as antibodies, for example, may be separated in this way. Protein separation by centrifugation can be predicted by simulation software, such as EPS Rate Zonal Run (Beckman Coulter, Fullerton Calif.). In isopycnic separation the particles migrate through the solvent gradient until they reach the point where their density is equal to that of the gradient, i.e. the isopycnic point. Once the particles have reached their isopycnic point they will no longer move in the gradient, regardless of how much longer the centrifuge is run for. Isopycnic gradients include cesium chloride gradients, for example.
- Density gradients can be used to affect protein or cell separation using a concentrator device of the invention. There are two types of density gradients: step-wise gradients and continuous gradients. Step gradients are prepared by successively layering solutions of different density in the centrifuge chamber and then layering the sample to be fractionated on top of the last “step”. Step gradients are useful in density gradient centrifugation because the abrupt density steps can be used as surfaces on which particles can sediment during centrifugation. This results in discrete particle layers at each step. The gradient can be built up in the centrifuge rotors or tubes, carefully layering one step on another, beginning with the densest step, by use of a pipette, or other mechanical or syringe means. Alternatively the gradient can be formed beginning with the least dense step by depositing each layer at the bottom of the centrifuge chamber through a narrow cannula or by other mechanical or syringe means. Continuous density gradients are gradients in which the density changes smoothly and continuously from one limit or extreme to another. Such gradients can be produced from step gradients by allowing sufficient time for diffusion to smooth out the steps, but continuous gradients are normally prepared directly by using special devices known as gradient makers or gradient engines.
- Body fluids can be concentrated using a concentrator device of the invention by density gradient methods. In embodiments, the body fluids are autologous body fluids. At the conclusion of centrifugation, the density gradient and the separated particles, cells or proteins and desired fluid layer(s) can be removed from the rotor and collected as a series of fractions.
- In embodiments, one or more fluid fractions collected from the concentrator device correspond to concentrated body fluids. Various different concentrated body fluids can be prepared by centrifugation or gravitational weight separation including, without limitation, blood fractions (platelet rich plasma (PRP), platelet poor plasma (PPP)), stem cells (cord blood-derived and bone marrow-derived) for example, concentrated seminal fluid, concentrated spinal fluid and the like. In an embodiment, the fluid fractions are concentrated to concentrations of about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:100, about 1:200, about 1:500, or about 1:1000. In an embodiment, the one or more components in a concentrated fluid fraction is concentrated about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:100, about 1:200, about 1:500, or about 1:1000 compared to the same one or more components in the unconcentrated fluid. In an embodiment, the fluid fractions are concentrated to concentrations from about 1:20 to about 1:50, from about 1:20 to about 1:100, from about 1:50 to about 1:100, from about 1:50 to about 1:200, from about 1:100 to about 1:200, from about 1:200 to about 1:500, from about 1:200 to about 1:1000, or from about 1:500 to about 1:1000. In an embodiment, one or more components in a concentrated fluid fraction is concentrated from about 1:20 to about 1:50, from about 1:20 to about 1:100, from about 1:50 to about 1:100, from about 1:50 to about 1:200, from about 1:100 to about 1:200, from about 1:200 to about 1:500, from about 1:200 to about 1:1000, or from about 1:500 to about 1:1000 compared to the same one or more components in the unconcentrated fluid. In some embodiments, the concentrator of the invention preserves or maintains the physiological ratios of the components in the body fluid fraction. The exact ratio of each component is not significant, as long as the relative physiological ratios are maintained during concentration.
- In an embodiment, a concentrated and filtered fraction of autologous fluid obtained by a concentration device of the invention is administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, or about 4 hours from the time of isolation of the antilogous fluid from the subject.
- Concentrated body fluids obtained by the methods of the invention can be used in a wide variety of applications, including, without limitation, surgical applications, preparation of allograft materials for implants, tissue regeneration or tissue culture, stem cell growth or separation, seminal fluid fractionation, protein separation, and DNA purification. In embodiments, the concentrated biological fluids of the invention are autologous body fluids.
- The concentrator of the invention can be used to obtain concentrated fractions of blood or plasma, including platelet rich plasma (PRP) and platelet poor plasma (PPP). In embodiments, the concentrator of the invention is used to obtain concentrated PRP from a sample of patient blood during surgery for use in surgical applications, such as bone healing. In an embodiment, whole blood is withdrawn from the patient, and centrifuged in the concentrator of the invention for 5 to 30 minutes at 25 to 1000 g, and in another embodiment, the whole blood is centrifuged for about 15 minutes at 400 g. The central PRP layer of the centrifuged blood is visually identified by color and withdrawn from the separation chamber. The PRP layer is passed through the filter unit under syringe pressure for one to ten passes, and in an embodiment, the PRP layer is passed through the filter for 6 passes. The filtration can be tangential flow or dead end. In an embodiment, tangential flow filtration using hollow filter fiber membranes with a size cutoff of 0.1 nm to 100,000 nm and a surface area of 1 cm2 to 6000 cm2 is used. This results in the production of concentrated PRP. The concentrated PRP obtained has a thick, gel-like consistency, having an increased concentration of platelets and white blood cells as compared to whole blood. With the higher concentration of platelets, the resultant material includes a higher concentration of growth factors from the blood. The resultant concentrated PRP product can be directly applied to, for example, a fractured or damaged bone during surgery, a wound, a surgical incision, or damaged tissue. In an embodiment, the concentrated PRP obtained by the concentrator can be a bone growth stimulant applied directly to the injured or fractured bone, wound, surgical incision or damaged tissue. The higher concentration of the patient's own growth factors obtained from the patient's blood induce a faster healing rate for the bone, reduce low grade infection around the surgical site or wound, and reduce soft tissue inflammatory response. If desired, various known diluents, such as buffered saline, may be used to adjust the viscosity of the autologous concentrated PRP for various applications.
- In other embodiments, a concentrator of the invention is used to obtain concentrated PRP from a sample of patient blood during surgery, for use in surgical applications such as cartilage healing. The resultant concentrated PRP product is surgically applied directly to a site of damaged, wounded or severed cartilage. If desired, the concentrated PRP can be mixed with chondrocytes obtained from the patient or a different source. In an embodiment, chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage with pronase and collagenase. In an embodiment, the cartilage is autogenic/autologous, allogenic or xenogenic. In an embodiment, the cartilage is derived from mammalian sources, including human, porcine and bovine sources. The concentrated PRP can also be mixed with artificial polymer or collagen-based cartilage replacement products to improve integration of the cartilage defect repair substance and to enhance anchoring of the cartilage defect repair substance.
- By applying the concentrated PRP obtained by the concentrator of the invention as a cartilage repair growth stimulant directly to the cartilage site, the higher concentration of growth factors obtained induces a faster healing and ingrowth rate for the cartilage, reduce low grade infection around the surgical site, and reduce soft tissue inflammatory response. In an embodiment, the concentrated PRP is an autologous fluid obtained from the patient's own blood.
- In some embodiments, concentrated PRP is obtained as described above, and the concentrated PRP is applied either between two locations of soft tissue such as at a surgical incision, in between stitched tissue, etc., or as a salve or balm over a section of damaged soft tissue, such as over a burn site, laceration or abrasion. Concentrated PRP used as a salve or balm causes delivery of additional growth factors and blood proteins to the tissue healing site, resulting in faster wound closure and healing. While not wishing to be bound by a particular theory, it is believed that the concentrated PRP used in a salve or balm for soft tissue healing induces or promotes an effective increase in one or more of cytoplasmic granules, serotonin, ADP, Thromboxane A2, factors III, V, VII, X, XI and/or XII, platelet thromboplastic factor (PF3), and prothrombin activator.
- In some embodiments, the concentrated PRP of the invention is used as a platelet glue wound sealants. These sealants are discussed in U.S. Pat. Nos. 5,733,545, 6,010,627 and 6,342,157, incorporated by reference. Concentrated PRP can be obtained by a concentrator of the invention as described above. The resultant concentrated PRP is a sticky gel-like material, which can be used similar to surgical glue to adhere two tissue portions together.
- If desired, concentrated PRP of the invention can be mixed with other surgical glue materials to increase the adhesive characteristics, increase the yield volume, and/or adjust the spreadability of the resultant mixture. For instance, a common class of tissue adhesives is fibrin-based and contains a concentrate of fibrinogen and thrombin. The fibrin adhesives are typically two-component adhesives that when mixed together react to simulate the last stages of the clot-forming cascade. The resulting clot adheres to tissue and bridges a gap therebetween until healing can occur. The concentrated PRP of the present invention can be mixed with any of these known biologically presourced, tissue adhesives.
- The concentrated PRP in the surgical glue causes delivery of additional growth factors and blood proteins to the tissue healing site, resulting in faster wound closure and healing. While not wishing to be bound by a particular theory, it is believed that the concentrated PRP used in a salve or balm for soft tissue healing induces or promotes an effective increase in one or more of cytoplasmic granules, as described above with regard to concentrated PRP used as a salve or balm.
- In some embodiments, other fluids, including platelet poor plasma (PPP) can be used as surgical glue materials. For example, the concentrator of the invention is used to obtain concentrated PPP from a sample of patient blood during surgery. In an embodiment, whole blood is withdrawn from the patient, and centrifuged in the concentrator of the invention for 2 to 30 minutes at 250 to 10000 g. In another embodiment, withdrawn blood from the patient is centrifuged in the concentrator of the invention for about 5 minutes at 6500 g. The PPP layer of the centrifuged blood is visually identified by color and withdrawn from the centrifuge chamber. The PPP is passed through the filter unit under syringe pressure for one to ten passes, and in an embodiment, for 4 passes. If desired, the PPP can be cooled prior to filtration to accelerate precipitation separation, such as down to 1 to 10° C. The filtration results in a concentrated PPP. The concentrated PPP obtained is a viscous liquid, having an increased concentration of fibrinogen, thrombin, clotting factors and associated proteins and structures as compared to whole blood. Various known diluents, such as buffered saline, can be used to adjust the viscosity of the autologous concentrated PPP for various applications.
- The resultant concentrated PPP product can be used as an essential ingredient in formulating a high fibrin glue. If a cooling step was applied to the platelet poor plasma, the high fibrin glue can be reheated to about 37° C. for application to the patient.
- If desired, the high fibrin glue can be mixed with commercially available sealant preparations, such as TISSEEL from Baxter International of Deerfield, Ill. or with cyanoacrylate tissue adhesives such as DERMABOND of Ethicon of Somerville, N.J. The high fibrin glue helps produce a stable, flexible and elastic fibrin bioactive matrix, which firmly adheres to exposed collagen, similar to those formed more slowly during physiologic blood coagulation. The autologous PPP glue of the present invention can also be mixed with glues based on gelatin cross-linked with an aldehyde, such as gelatin-resorcinol cross-linked with formaldehyde (GRF) or glutaraldehyde (GRFG), or with tissue glues derived from cyanoacrylates, polyurethanes, polymethylmethacrylates, among other synthetic polymers.
- The high fibrin glue can be used during surgery, such as during thoracic, cardiovascular, and general surgical operations, and in orthopedic procedures such as fixation of chondral fragments, chondral chips and osteochondral fragments. The high fibrin glue can also be used as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of splenic injuries due to blunt or penetrating trauma to the abdomen, when control of bleeding is important. The high fibrin glue can also be used for incisional or laceration repair. These uses of fibrin glue in accordance with the invention provide a flexible water-resistant protective coating to the repaired tissue and may eliminate the need for suture removal. The high fibrin glue can also be used to adhere drug delivery matrices, or other such overlays that can be used in conjunction with autograft, allograft, or xenograft materials, such as ligaments, bone tissue, skin, tendons, cartilage and the like.
- In some embodiments, concentrated PPP obtained by the methods of the invention is used for cartilage healing. Concentrated PPP is obtained as described above. The concentrated PPP can be applied as a cartilaginous repair material directly to a cartilage defect. If desired, the concentrated PRP can be mixed with chondrocytes obtained from the patient or a different source. In an embodiment, chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage with pronase and collagenase. The concentrated PPP can also be mixed with artificial polymer or collagen-based cartilage replacement products to improve integration of the cartilage defect repair substance and to enhance anchoring of the cartilage defect repair substance.
- A concentrator of the invention can be used, for example, to obtain concentrated fluids or concentrated autologous fluids such as autologous concentrated PRP, PPP, growth factors, differentiation factors, chemotactic factors, adhesion molecules, or stem cells for use in surgical applications. In an embodiment, a graft material is an allogenic or xenogenic material, derived from mammalian sources including human, bovine and porcine sources. In an embodiment, autologous concentrated PRP, PPP, growth factors, differentiation factors, chemotactic factors, adhesion molecules, stem cells, or a combination thereof are applied to an organ or tissue from a genetically non-identical donor prior to or during transplanting of the organ or tissue. Such application to the allograft or xenograft results in increased acceptance of the new organ or tissue from the recipient's immune system and decreased rejection, aids in regeneration of tissue around the new organ or tissue, and further helps decrease healing time from the transplant surgery.
- A concentrator of the invention can be used to obtain a concentrated fluid containing one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules or a combination thereof from a body fluid for use in the preparation of graft materials for implantation. In an embodiment, the concentrated fluid is PRP, PPP, or PRP+PPP. In an embodiment, the concentrated fluid is autologous. The graft material can be coated to provide controlled release of proteins such as one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or combination thereof from a surface of the graft material. The graft material can be coated with a layer of polymeric material. Solubility or insolubility of the polymeric material can be engineered to control the release the one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or combination thereof of bioactive molecules from the polymeric coating. In an embodiment, the rate of release is determined by the rate of degradation and/or dissolution of the polymer or copolymer comprising the coating.
- In an embodiment, the polymer layer comprises one or more reactive functional groups that can react with or covalently bind one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or a combination thereof present in the concentrated autologous fluid. Examples of suitable polymeric materials include but are limited to EUREKA DUET in-situ forming matrix, EUREKA DUET biodegradable device matrix, ENCORE drug delivery polymer matrix, SYNBIOSYS biodegradable drug delivery polymer system, CAMEO biodegradable polymeric drug delivery matrix, POLYACTIVE biodegradable polymeric drug delivery matrix, CELLABRATION encapsulation polymer matrix, and PHOTOLINK (Surmodics, Minneapolis, Minn.). The concentrated body fluid or autologous fluid can be used to reconstitute graft material, which is typically in a freeze-dried form. Reconstituting the graft material with an autologous concentrated fluid such as PRP provides increased acceptance of the tissue at the transplant site and speeds healing after graft surgery.
- In other embodiments, a coating agent comprises a nonpolymeric core molecule having attached thereto, either directly or indirectly, one or more substituents comprising negatively charged groups or reactive species that can interact with positively charged moieties on growth factors, differentiation factors, chemotactic factors, adhesion molecules and the like in the concentrated fluid. In an embodiment, the coating agent comprising a nonpolymeric core molecule having attached thereto, directly or indirectly, one or more substituents comprising negatively charged groups or reactive species that can interact with positively charged moieties of one or more growth factors, differentiation factors, chemotactic factors, adhesion molecules, or a combination thereof. In accordance with the invention, reactive species comprise one or more first reactive species adapted to attach the coating to a surface, and one or more second reactive species adapted to initiate polymerization. In embodiments, the polymer layers are coated with biodegradable layers of nanoscale polysaccharides, antimicrobial agents, antifungal agents, biologically active macromolecules, such as proteins, peptides and amino acid analogs, for example, and the like. In other embodiments, the polymer layers are coated with cells, cell agglomerates or cell matrices. The polymer layers and methods for making such polymer layers are known in the art, and are further described in, for example, U.S. Pat. No. 6,514,734, incorporated herein by reference.
- In other embodiments, the graft material is coated with a nanofiber or microfiber. The nanofiber or microfiber comprises one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or a combination thereof. The molecules can be attached to the surface of the fiber, such as for example by a functional group or charged moiety, or added to the polymer solution prior to electrospinning. In an embodiment, functional groups are deposited on the growth surface by plasma deposition. Plasma deposition creates local plasmas on the surfaces of the fibers. The treated surface is then reacted with gaseous molecules, such as allylamine and/or allyl alcohol, in a reaction chamber. In another embodiment, functional groups are introduced during manufacturing of the fibers. For example, dodecyl amine, dodecyl aldehyde, dodecyl thiol, or dodecyl alcohol can be added to a polymer solution during the manufacturing process. A portion of the added amines, aldehydes, sulphydryl, or alcohol moieties, respectively, are exposed at the surface of the fiber. Examples of suitable nanofibers and microfibers are described, for example, in U.S. 2005/0059695, WO 2006/094076, U.S. 2007/0082393, and are commercially available, for example, from Surmodics (Minneapolis, Minn.).
- Solubility or insolubility of the nanofibers or microfibers can be engineered to control the release the one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or combination thereof of bioactive molecules from the nanofibers or microfibers. In an embodiment, the rate of release is determined by the rate of degradation and/or dissolution of the polymer or copolymer comprising the nanofiber or microfiber.
- In some embodiments, above void filter, such as demineralized bone matrix (DBM) is reconstituted in and/or coated with a concentrated fluid obtained from a concentrator of the invention. In an embodiment, the fluid is concentrated autologous PRP. The concentrator can used to obtain concentrated PRP from a sample of patient blood during surgery. The concentrated PRP can be mixed with a bone void filler, such as DBM. Suitable DBMs can be obtained from LifeNet of Virginia Beach, Va. under the names CELLECT, CEL25, DCAN5 (Demineralized Cancellous 1-4 mm), DGC20 or DGC 40 (Demineralized Cortical Bone), GDS005 GDS 010 or GDS015 (I/C Graft Chambers), OPTIUM Gel AGEL05 or AGEL10 (for non-weight bearing applications), OPTIUM Putty APUT05 or APUT05 (for non-weight bearing applications), and from Osteotech, Inc. of Eatontown, N.J. under the names GRAFTON DBM CRUNCH and GRAFTON DBM MATRIX PLF. The DBMs can be freeze dried for subsequent use for mixing with the concentrated platelet rich plasma during surgery. Once mixed with the bone void filler, such as DBM, the resultant mixture is applied during surgery in any of numerous applications, including, without limitation, spinal fusion, spinal defects, trauma, bone cysts, bone tumors, fracture management, filling of osseous defects, augmenting total joints, sinus augmentation, ridge preservation, joint revisions, posterolateral fusion procedures and general orthopedics applications. Mixing the patient's own concentrated PRP with bone void filler for surgical application back into the patient results in increased osteoconductivity and faster bone growth. The bone void filler material is more likely to be readily accepted by the patient's immune system and a lower chance of rejection, and aids in regeneration of bone tissue around the bone void filler material.
- Concentrated fluids obtained by the methods of the invention can be used in tissue regeneration, tissue culture, and cell culture. Concentrated fluids comprising one or more growth factors, differentiation factors, chemotactic factors, adhesions molecule, or a combination thereof can be added to a growth matrix or added directly to tissue or cell culture media. In an embodiment, the concentrated fluid is applied to the site of a wound or injury in order to promote proliferation of cells and repair and regeneration of tissue in the wound site.
- The filter housing of a concentrator of the invention can be configured as a growth chamber. In such an embodiment, the filter housing is fitted with a growth matrix or growth surface. Examples a growth matrix or growth surface include but are not limited to a network of one or more nanofibers, a nanofibrillar structure, glass, silicon or plastic comprising an etched or micropatterned surface, glass, silicon or plastic surface comprising macropores or nanopores, a polymer scaffold, a woven scaffold, a woven or net textile, an extruded scaffold, a rod, a screw, a wire, a mesh, or a cage. In some embodiments, the growth matrix or growth surface can be glass, polymeric, metallic, ceramic, cellulosic, or proteinaceous. In some embodiments, a surface of the growth matrix is coated with nanofibers or a polymeric coating that supports the growth and/or attachment of cells seeded on or to the surface. An example of a suitable surface includes, but is not limited to, a surface of a rod, screw, wire, mesh, or cage. Examples of nanofibers and/or polymeric coatings that support the growth and/or attachment of cells to or on a coated surface are described herein and are known in the art.
- In an embodiment, the growth matrix is a nanofibrillar structure. The nanofibrillar structure can be layered to form a multi-layered nanofibrillar assembly. A diverse array of growth environments for a cell or tissue can be constructed by engineering specific chemical and physical properties into the nanofiber network, substrate, and/or spacers comprising the individual nanofibrillar structure and/or sequentially layering individual nanofibrillar structures.
- Specific nano- and/or micro-environments can be engineered within individual nanofibrillar structures or within an assembly comprising two or more layered nanofibrillar structures. Physical properties and/or characteristics of individual nanofibrillar structures including, but not limited to, surface roughness, adhesivity, porosity, solidity, elasticity, geometry, interconnectivity, surface to volume ratio, fiber diameter, fiber solubility/insolubility, hydrophilicity/hydrophobicity, fibril density, and fiber orientation can be engineered to mimic the nanotopography of ECM or BM. For example, the physical and geometric properties of the nanotopography of the individual nanofibrillar structures of the assembly can be engineered to mimic the nanotopography of the extracellular matrix or basement membrane.
- Specific recognition motifs such as peptides, polypeptides, lipids, carbohydrates, amino acids, nucleotides, nucleic acids, polynucleotides, or polysaccharides including, but not limited to, growth factors, differentiation factors, fibrous proteins, adhesive proteins, glycoproteins, functional groups, adhesive compounds, and targeting molecules can be engineered into the nanofibrillar network, substrate, and/or spacers of the individual nanofibrillar structures or multi-layered assembly either isotropically or as gradients to promote appropriate cellular activity, including cell growth and/or differentiation. Embodiments involving amino acids, peptides, polypeptides, and proteins can include any type of such molecules of any size and complexity as well as combinations of such molecules. Examples include, but are not limited to, structural proteins, enzymes, growth factors, differentiation factors, and peptide hormones.
- Nanofibrillar growth matrices and methods of using growth matrices for cell proliferation and differentiation and culturing cells or tissue are described in detail, for example, in U.S. 20050095695 and WO 2006/094076, incorporated herein by reference.
- In an embodiment, a fluid, cells, or tissue is added to the separation chamber of a concentrator of the invention and the concentrator is centrifuged or separated by gravitational weight. In an embodiment, the tissue is disrupted tissue. In an embodiment, the fluid, cells, or tissue are autologous. A desired cellular fraction is removed from the separation chamber and transferred via the transfer ports to the filter chamber comprising a growth matrix. The cells can be cultured on the growth matrix within the concentrator or the growth matrix can be removed and cultured separately. Cells or tissue can be grown on the growth matrix in vivo, in vitro, or ex vivo using known methods and conditions. Cells useful in the methods of the invention include stem cells, somatic cells, committed stem cells, differentiated cells, and tumor cells. The cells can be from a mammal. The mammal can be human. The cells can be a tissue. Examples of tissue include skin, bone, liver, heart, kidney, bladder, muscle, ligament, tendon, cartilage, brain, retina, cornea, and pancreas. Examples of cells useful in the methods of the invention include, but are not limited to, osteoblasts, myoblasts, neurons, fibroblasts, glioblasts, germ cells, stem cells, hepatocytes, chondrocytes, keratinocytes, smooth muscle cells, cardiac muscle cells, connective tissue cells, glial cells, epithelial cells, endothelial cells, hormone-secreting cells, neurons, and lymphoid cells such as B cells, T cells, macrophages, and neutrophils. Examples of stem cells include, but are not limited to, embryonic stem cells, mesenchymal stem cells, bone marrow stem cells, and umbilical cord stem cells. The stem cells can be mammalian stem cells. In an embodiment, the stem cells are human. In an embodiment, the stem cells are embryonic stem cells.
- The cells can be from the recipient, a nonspecific donor from the same species, or a donor from a different species. The cells can be from the tissue of a transgenic animal wherein the cell has been engineered to express one or more polynucleotides, repress the expression of one or more polynucleotides, or both. An example of genetically engineered cells useful in the methods of the present invention is cells engineered to make and secrete one or more desired bioactive molecules. When these cells are implanted in an organism or patient, the bioactive molecules produced by the cells can produce a local effect or a systemic effect. Examples of bioactive molecules include growth factors, differentiation factors, and hormones. Examples of hormones include insulin, human growth factor, erythropoietin, thyroid stimulating hormone, estrogen, or progesterone. Cells can be engineered to produce an antigen. These cells can be implanted into an organism or patient to produce an immune response. Cells can be engineered to produce bioactive molecules that inhibit or stimulate inflammation, facilitate healing, resist immuno-rejection, provide hormone replacement, replace neurotransmitters, inhibit or destroy cancer cells, promote cell growth, inhibit or stimulate formation of blood vessels, augment tissue, and promote or induce supplementation or replacement of skin, synovial fluid, tendons, cartilage, ligaments, bone, muscle, organs, dura, blood vessels, bone marrow, and extracellular matrix.
- Genetic engineering can involve, for example, adding or removing genetic material to or from a cell, altering existing genetic material, or both using standard recombinant methods. Embodiments in which cells are transfected or otherwise engineered to express a polynucleotide can use transiently or permanently transfected polynucleotide, or both. Polynucleotide sequences can be full or partial length, cloned or naturally occurring.
- In some embodiments, the concentrated fluid of the invention is a fluid comprising bone marrow-derived stem cells. In an embodiment, the concentrated fluid is autologous. In an embodiment, a surgeon inserts a large needle directly into the bone marrow cavity of bones of the lower back, of a patient and aspirates bone marrow out of the bones by inserting the needle into the bone multiple times. The aspirated bone marrow is then centrifuged in a concentrator of the invention, such as at 400 g for 5 minutes. The aspirated bone marrow is a blood-like substance with sufficiently different cell and molecule sizes and weights that the centrifuging process induces separation of the bone marrow into different fractions. If desired, prior to centrifuging the aspirated bone marrow can be mixed with 0.56% (0.075 M) KCl (0.56 g in 100 ml deionized water). The bottom layer is then removed and filtered at 1 to 10 and preferably 4 passes through the filter. The layers are filtered using a filtration system comprising a filter element or membrane as described elsewhere in this Application.
- In some embodiments, the concentrated fluid is a fluid comprising cord blood-derived stem cells. In an embodiment, blood is obtained from an umbilical cord during birth. The cord blood can be centrifuged in a concentrator of the invention, such as at 400 g for 5 minutes, thereby inducing separation of the cord blood into different fractions. The bottom layer is removed and filtered at 1 to 10 and preferably 4 passes through the filter, thereby obtaining a substance with an increased concentration of cord blood derived stem cells. The layers are filtered using a filtration system comprising a filter element or membrane as described elsewhere in this Application.
- The collection window of the device is infinitely adjustable along the column of the centrifuged body fluid, allowing more accurate collection of the concentrated autologous bone-marrow-derived stem cells. The fluid collected with the stem cells can be used for binding the cells and chips bone material. The fluid collected with the stem cells also helps maintaining the viability of the stem cells for a longer period of time by maintaining a consistent environment for the stem cells.
- The resulting concentrated stem cells are then injected or applied within a patient at a particular location of interest. In some embodiment, the stem cells are injected or administered with a carrier, such as DBM. For example, concentrated stem cells can be injected into the brain as a treatment for brain damage or into or adjacent the spinal cord after a spinal cord injury or disease such as ALS (Lou Gehrig's disease). The concentrated stem cells can be injected into a muscle which has undergone muscle damage, particularly into the heart such as for the treatment of non-ischemic (idiopathic) and ischemic heart failure. The stem cells can be injected into the circulatory system or back into the bone marrow to increase red blood cell production. The concentrated stem cells can be placed into the gums to form tooth buds, can be placed into the cochlea to induce cochlear hair cell regrowth as a treatment for deafness, or can be transplanted over a damaged retina as a treatment for blindness. The concentrated stem cells can be topically applied to treat a soft tissue wound or burn or similar injury. The concentrated stem cells can be added to an injured or fractured bone to facilitate bone healing. The concentrated stem cells can also be used for diagnosis purposes.
- A concentrator and methods of the invention can be used for sperm selection. In an embodiment, the concentrator device can be used to collect sperm and select either X- or Y-genotype sperm from a sample of mammalian seminal fluid. These methods are predicated on the fact that the two sperm genotypes of mammals (X and Y) may be separated according to pH or density characteristics. In an embodiment, the sperm is obtained from a livestock mammal, such as a bovine, horse, pig, sheep, or goat. For separation by density characteristics, application of buoyant forces within a liquid separation medium causes more buoyant sperm to obtain a different level in the separation medium than less buoyant sperm. When a sample of seminal fluid is centrifuged using the device of the invention, the fluid is separated into fractions containing either the X or the Y-genotype sperm because of the difference in density of each genotype. When the sample of seminal fluid is a sample from a human patient, separation into X and Y-genotype sperm requires the application of a pH gradient in the concentrator of the invention. Substantially pure sperm fractions (having either X or Y-genotype characteristics) are isolated as either the top layer or the bottom layer of the concentrated fluid obtained from the device of the invention. Under certain circumstances, separation of the sperm into fractions or concentration in one particular genotype is enhanced by the application of pressure (positive or negative) to the filtration element or filter membrane of the device. Methods for density separation of sperm are known and described, for example, in U.S. Pat. No. 4,327,177, incorporated herein by reference.
- The concentrator and methods of the invention can used for protein selection or separation. In an embodiment, the proteins can be growth factors, differentiation factors, chemotactic factors, or adhesion molecules. Proteins from the following general classes can also be used with the methods of the invention: prealbumins (thyroxine- and retinol-binding proteins), albumins, α- and β-globulins, apolipoproteins, coagulation proteins, cell-related plasma proteins, immunoglobulins, amyloid proteins and the like. These protein families and individual proteins, derived from Frank Putnam “The Plasma Proteins”, Volume IV, 2nd Edition, 1984, are provided in Table I.
-
TABLE I Plasma Proteins Subunit Protein Species Structure Chain Length MW Prealbumin, thyroxine-binding Protein Human Noncovalent 127 54,980 tetramer of identical chains Prealbumin, thyroxine-binding Retinol-binding protein Protein Human Single chain 182 20,957 Retinol-binding protein Albumin Protein Human Single chain 585 66,458 Albumin Nucleic acid 609 69,365 precursor Bovine Single chain 582 66,210 Nucleic acid 606 precursor Porcine Single chain ~575 ~66,300 Ovine Single chain 575 ~66,300 Chicken Single chain 575 ~66,300 Rat Single chain 584 64,600 Nucleic acid 608 precursor α-Globulins Protein α-Globulins Human Single chain 167 26,000 α1-Microglobulin Human Single chain 181 40,000 α1-Acid Rat Nucleic acid 187 ~40,000 glycoprotein precursor Human Single chain 394 54,000 α1-Antitrypsin Nucleic acid precursor Baboon Nucleic acid 394 ~54,000 precursor Human Single chain ~440 68,000 α1- 408 Antichymortrypsin Human Single chain 65,000 α2-Antiplasmin Human Nucleic acid 590 66,300 precursor α1-Fetoprotein Rat Nucleic acid precursor Mouse Nucleic acid 586 72,000 precursor 9.5 S α1- Human Two (182)10 ~250,000 Glycoprotein pentagons (10 non-covalently bound identical subunits) (serum amyloid P Human Possibly a ~480 68,000 component) single chain α1B-Glycoprotein Human Single chain ~776 85,000 α1T-Glycoprotein Human Single chain ~450 52,000 Vitamin D-binding protein (Gc globulin) Human Single chain 54,000 Thyroxine-binding Human Single chain ~160,000 protein Inter-α-trypsin Human Single chain 1,046 132,000 inhibitor (easily cleaved) Ceruloplasmin Human Single chain ~440 ~58,500 3.8 S Histidine-rich Human Single chain ~213 81,000 α2-glycoprotein Galactoglycoprotein Human Single chaine 312 50,000 3.1 S Leucine-rich Rat (male) Nucleic acid 162 18,709 α2-glycoprotein precursor α2μ-Globulin Human Single chain ~258 41,000 Zn-α2-Glycoprotein Human Two chains (A ~359 49,000 & B) α2HS-Glycoprotein B chain 27 3,386 Human 4 identical 1,450 725,000 subunits α2-macroglobulin Human Single chain ~465 60,000 4S-α2,β1- Human 2 pairs of 656 86,018 Glycoprotein nonidentical chains (αβ)2 Haptoglobin Single-chain 245 precursor α1 chain 83 9,189 α2 chain 142 15,939 β chain 245 33,820 β chain Canine One pair of chains (αβ) β chain Human Single chain 52,000 Corticosteroid- Human Tetramer 220,000 binding globulin 8 S α3-Glycoprotein β-Globulins Protein A trimeric (42,300)n aggregate Pregnancy-specific Human Single chain 678 79,550 β1-glycoprotein Human Transferrin 679 Chicken Single chain 686 77,770 Ovotransferrin Nucleic acid 686 precursor Human Single chain 439 60,000 Hemopexin Rabbit Single chain ~440 57,000 Human Single chain 99 11,731 β2-Microglobulin Mouse Single chain 99 Rabbit Single chain 99 Guinea pig Single chain 99 Human Subunits 187 (20,946)5 aggregate as cyclic pentamers C-Reactive protein Rabbit Pentagonal 186 structure Human Single chain 326 ~50,000 β2-Glycoprotein I Human Single chain, 35,000 forms complex β2-Glycoprotein III Apolipoproteins Protein Human Single chain; 243 28,076 no disulfides Apolipoprotein A-I Human Dimer of 2 77 17,414 (HDL) identical chains, joined by disulfide Apolipoprotein A-II Human Single chain; 57 6,631 (HDL) no disulfides Apolipoprotein C-I Human Single chain; 78 8,829 (VLDL) no disulfides Apolipoprotein C-II Human Single chain 79 8,764 glycopeptide Apolipoprotein C-III Human Single chain 299 34,183 (VLDL) Apolipoprotein E γ-Mobility (non- immunoglobulin) Protein Human Single chain 47 5,100 0.6 S γ2-Globulin Human Single chain 132 14,000 2 S γ2-Globulin Human Single chain ~85 9,000 Basic Protein B2 Human Single chain 120 13,248 Post-γ-Globulin (γ- trace) Complement Components Protein Human Six identical 410,000 nocovalently- linked subunits, each with three similar chains (A, B&C) Total of 18 chains C1q B chain 226 C chain ~200 Human Noncovalent (83,000)2 dimer C1r Human B chain 242 27,096 C1r Human Single chain 83,000 C1s Human Two chains (a 83,000 and b) C1s Human Single chain 102,000 C2 Human Two disulfide- ~1,630 ~185,000 bonded chains C3 α chain ~960 115,000 β chain ~670 75,000 Mouse ProcC3 is a ~190,000 single-chain precursor Human Fragment of 77 9,093 C3 a chain C3a Porcine Fragment of 77 ~9,000 C3 α chain Rat Fragment of 78 ~9,000 C3 α chain Mouse Fragment of 78 ~9,800 C3 α chain Human Three disulfide- bonded chains C4 α chain ~785 93,000 β chain ~660 75,000 γ chain ~250 33,000 Human Fragment of a 77 8,763 chain C4a Bovine Fragment of a 77 chain Human Two disulfide- 185,000 bonded chains C5 α chain ~960 115,000 β chain ~670 75,000 Human Fragment of α 74 8,274 chain C5a Human Single chain ~900 1,048,000 C6 Human Single chain ~800 92,400 C7 Human Two 163,000 noncovalently- linked subunits C8 Human Disulfide- 540,000 bonded subunits (Mr 75,000) C4-Binding Protein Human Single chain 24,000 Factor D (C3 Human Single chain 90,000 Proactivator Convertase) Factor B (C3 Bb Fragment 505 60,000 Proactivator) Human Four non- ~480 220,000 covalent identical chains Properdin Human Single chain ~1,275 155,000 Factor H (β1H) Human Two disulfide- 90,000 bonded chains C3b-Inactivator Light chain 40,000 Heavy chain 50,000 Coagulation Proteins Protein Human Single chain 581 72,000 Prothrombin Bovine Single chain 582 72,000 Bovine Two disulfide- ~340 37,000 linked chains Thrombin A chain 49 5,728 B chain 259 31,000 Human Single chain 48,000 (two chains when activated) FactorVII Human Noncovalent (100,000)n complex Factor VIII Human Single chain 462 51,801 Precursor Factor IX Bovine Single chain 427 ~55,000 Human Heavy and 381 light chains Factor IXa Light chain 145 (activated) Heavy chain 236 Bovine Heavy and 390 ~46,500 light chains Light chain 146 16,600 Heavy chain 232 27,300 Human Heavy and 59,000 light chains Factor X Light chain 139 16,211 Bovine Heavy and 447 55,000 light chains Light chain 140 16,143 Heavy chain 307 38,000 Bovine Heavy and 396 44,000 light chains Factor Xa Activated Light chain 140 16,000 Heavy chain 256 28,000 Human Two identical 130,000 disulfide- linked chains Factor XI Bovine Two disulfide- 415 55,000 linked chains Protein C Light chain 155 21,000 Heavy chain 260 35,000 Human Single chain ~69,000 Protein S Bovine ~66,000 Bovine Single chain ~50,000 Protein Z Human Three pairs of 2,964 340,000 disulfide bonded chains Fibrinogen α chain 610 64,115 β chain 461 52,314 γ chain 411 46,468 Human Single chain 790 ~92,000 Plasminogen Two-chain 790 after activation Plasmin Heavy chain 560 (A) Light chain (B) 230 Human Single chain 76,000 Factor XII Two pairs of 320,000 non-identical chains (a2b2) Factor XIII Bovine Single chain 621 (Transglutaminase) Precursor HMW and LMW Bovine Heavy chain 361 Prekininogens LMW Kininogen Light chain 47 Human Single chain 430 58,000 Antithrombin III Cell-Related Plasma Proteins Protein Human Disulfide- ~1,900 ~440,000 linked Dimer Fibronectin Human Disulfide- ~1,880 ~440,000 linked Dimer Human Tetramer of 81 35,404 identical chains β-Thromboglobulin Human Tetramer of 70 (7,769)4 identical chains Platelet Factor-4 Bovine Single chain 60 6,647 Serum Basic Protease Inhibitor Immunoglobulins (Antibodies) Protein Higher Four disulfide- (160,000)n Vertebrates bonded chains, two heavy and two light Immunoglobulins Human Monomer of ~214 ~23,000 (Antibodies) dimer κ or λ Light Chains Human Kappa (κ) ~214 ~23,500 (Bence Jones Proteins) Lambda (λ) ~214 ~23,000 Human (γκ)2 or (γλ)2 ~150,000 monomer Immunoglobulin G γ1 Heavy ~475 ~50,000 (IgG) chain IgG1 γ2 Heavy ~450 ~50,000 chain IgG2 γ3 Heavy ~475 ~55,000 chain IgG3 γ4 Heavy ~450 ~50,000 chain IgG4 Human (α2κ2)n or ~(160,000)n (α2λ2)n n = 1, 2 or 4 Immunoglobulin A α1 Heavy ~475 ~60,000 (IgA) chain IgA1 α2 Heavy ~450 ~60,000 chain IgA2 Human μ2κ2 or μ2λ2 ~950,000 monomer Immunoglobulin M μ Heavy chain ~575 ~75,000 (IgM) Human δ2κ2 or δ2λ2 ~510 ~175,000 monomer Immunoglobulin D δ Heavy chain ~65,000 (IgE) Human σ2κ2 or σ2λ2 ~190,000 monomer Immunoglobulin E σ Heavy chain ~550 ~72,000 (IgE) Human Single chain 129 14,619 J Chain Single chain 137 Precursor Amyloid Proteins (Non- Immunoglobulin) Protein Human Single chain 104 11,683 Precursor Amyloid-Related Human Single chain 76 9,150 Apoprotein Precursor (apoSAA1) AA (FMF) (ASF) Human Single chain 76 9,145 Precursor AA (TH) (AS) Human Ten Subunits ~184 ~25,000 aggregates as two pentamers Serum Amyloid P Component (9.5 S 7α1-glycoprotein) Misc. Trace Components Protein Human AA Carcinoembryonic Human AA Asp Antigen Angiotensinogen Rat Single chain 49,548 Asp Precursor NA - The basic methodology for protein selection and collection involves centrifuging or other gravity separation of a biological fluid or disrupted cells or tissue. The height or window of the column which contains the specific desired protein can be infinitely adjusted to select the desired protein and collect the fluid. As discussed herein, various filters can be used to further hone the concentration or concentrate specific proteins. This method of selection and collection helps to maintain protein viability and activity by maintaining their environment in the natural fluid.
- The proteins can be used, for example, for healing, surgical applications, therapeutic applications, tissue or cell culture, diagnostic purposes, or reapplied into a patient's body. In an embodiment, one of more growth factors, one or more differentiation factors, one or more chemotactic factors, one or more adhesion molecules, or a combination thereof is administered to bone, cartilage, a wound, soft tissue injury, or surgical site to promote healing. The concentrated proteins can also be mixed with stem cells. The cartilage can be wounded, damaged, or severed. The wound can be a surgical incision, abrasion, ulcer, burn, or any other break in the skin. In an embodiment, one of more growth factors, one or more differentiation factors, one or more chemotactic factors, one or more adhesion molecules, or a combination thereof is administered to a subject to treat an orthopedic disorder or during or after a surgical procedure to correct an orthopedic disorder to promote healing. The concentrated proteins can also be administered with stem cells. In an embodiment, the concentrated proteins and/or stem cells are administered to the surgical site. In an embodiment, the orthopedic disorder comprises spinal fusion, spinal defect, bone trauma, bone cyst, bone tumor, bone fracture, filling of osseous defect, joint augmentation, sinus augmentation, ridge preservation, joint revision, or posterolateral fusion.
- In an embodiment, fluid or tissue from the kidney can be autologously concentrated in a device of the invention to obtain concentrated specimens of or fractions containing erythropoietin, urodilatin, calcitrol, and/or rennin. Fluid or tissue from the spleen can be autologously concentrated to obtain concentrated specimens of or fractions containing opsonins, properdin, and tuftsin. Fluid or tissue from the liver can be autologously concentrated to obtain concentrated specimens of or fractions containing bile, hepatocytes, cholangiocytes, unipotential or bipotential stem cells, insulin-like growth factor (IGF); angiotensinogen, and/or thrombopoietin. Fluid or tissue from the thyroid can be autologously concentrated to obtain concentrated specimens of or fractions containing hormones, principally thyroxine (T4), triiodothyronine (T3) and/or calcitonin. Fluid or tissue from the hypothalamus can be autologously concentrated to obtain concentrated specimens of or fractions containing corticotropin-releasing hormone (CRH), dopamine, gonadotropin-releasing hormone (GnRH), growth hormone releasing hormone (GHRH), somatostatin thyrotropin-releasing hormone (TRH), and/or hypocretin. Fluid or tissue from the pineal gland can be autologously concentrated to obtain concentrated specimens of or fractions containing melatonin. Fluid or tissue from the pituitary gland can be autologously concentrated to obtain concentrated specimens of or fractions containing TRH (thyrotropin-releasing hormone), CRH (corticotropin-releasing hormone), DA (dopamine, “prolactin inhibiting factor”/PIF), GnRH (gonadotropin-releasing hormone), GHRH (growth hormone releasing hormone), prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, endorphins and/or growth hormones. Fluid or tissue from the parathyroid can be autologously concentrated to obtain concentrated specimens of or fractions containing Parathyroid hormone (PTH). Fluid or tissue from the heart can be autologously concentrated to obtain concentrated specimens of or fractions containing atrial natriuretic peptide. Fluid or tissue from the stomach and/or intestines can be autologously concentrated to obtain concentrated specimens of or fractions containing cholecystokinin (CCK), gastrin, ghrelin, neuropeptide, secretin and/or somatostatin. Fluid or tissue from the pancreas can be autologously concentrated to obtain concentrated specimens of or fractions containing insulin, glucagons, somatostatin, pancreatic polypeptide, paracrine, autocrine and/or other hormones produced in the Islets of Langerhans. Fluid or tissue from the adrenal glands can be autologously concentrated to obtain concentrated specimens of or fractions containing glucocorticoids (cortisol), mineralocorticoids (aldosternone), and/or androgens (DHEA & testosterone). Fluid or tissue from the testes can be autologously concentrated to obtain concentrated specimens of or fractions containing androgens and/or testosterone. Fluid or tissue from the ovary can be autologously concentrated to obtain concentrated specimens of or fractions estrogens (estradiol) and/or progesterone. Fluid or tissue from the placenta can be autologously concentrated to obtain concentrated specimens of or fractions containing progesterone, estrogens, human chorionic gonadotropin, and/or human placental lactogen. Fluid or tissue from the thalamus or other portions of the endocrine system can be similarly autologously concentrated.
- The concentrator and methods of the invention can be used for isolation and purification of DNA. In embodiments, the DNA can be genomic DNA, plasmid DNA, DNA isolated from tissues or cells, synthetic oligonucleotides, and the like. The basic methodology for DNA isolation and purification involves disrupting the DNA-containing cells or tissue by chemical or mechanical means. The disrupted cells or tissue are then filtered using the filter element and then centrifuged in the concentrator of the invention. The cell or tissue layer is retained on the filter element, while the application of pressure allows the DNA-containing fluid layer to pass through the filter and into the centrifuge chamber of the concentrator device. Centrifugation can be performed on the ultracentrifuge or microcentrifuge scale, at high speeds of up to 15,000 RPM. Various filters can be used to further hone the purification of DNA using the concentrator of the invention. For example, the filter element of the invention can be an affinity column on which DNA in a fluid is preferentially adsorbed and then eluted. The methods of the invention allow DNA to be purified in a simple and efficient manner, with minimal mechanical or chemical manipulation. Purified DNA obtained by the methods of the invention can be used for a variety of diagnostic and therapeutic purposes.
- In some embodiment, a concentrated fluid, such as PRP and/or PPP, can be applied to a hemostasis gauze or pad. The gauze or pad may be formed of a woven gauze material or a non-woven bandage material. The gauze or pad is preferably formed of a bioabsorbable material. Alternative, a non-woven bandage material may be filled with autologous concentrated PRP. In an embodiment, the hemostasis gauze or pad is applied to a wound site. The hemostasis gauze or pad can be directly applied to a site of bleeding to initially stop the bleeding, such as a vascular access sites after removal of a percutaneous catheter or tube, and then to accelerate tissue healing as the gauze or pad is bioabsorbed.
- In an embodiment, the hemostasis gauze or pad can be coated with or contain other known hemostasis agents. For example, concentrated PRP and/or PPP may be applied to a CHITO-SEAL topical hemostasis pad available from Abbott Vascular of Santa Clara, Calif., which is a soft, sterile, non-woven pad coated with chitosan. Chitosan is produced commercially by deacetylation of chitin (can be produced from chitin also), which is the structural element in the exoskeleton of crustaceans (crabs, shrimp, etc.). The concentrated PRP and/or PPP may also be applied to a pad containing thrombin separated from bovine plasma to enhance the hemostasis properties of the pad. Commercially available examples of thrombin-containing pads are available from Vascular Solutions of Minneapolis, Minn. as D-STAT DRY, D-STAT RADIAL, THROMBIGEL, D-STAT 2DRY and THROMBIX.
- Concentrated PRP and/or PPP obtained as described above can be used in flow hemostasis. The concentrated PRP or PPP can be autologous. Concentrated PRP and/or PPP can be applied directly in liquid form to the surface of a wound site. The concentrated PRP and/or PPP aids in inhibiting active bleeding from the wound by initiating the body's own clotting mechanisms. In an embodiment, autologous concentrated PRP and/or PPP is combined with other presourced procoagulent components, such as collagen and thrombin. The concentrated PRP and/or PPP can be used to stop any active surface bleeding, and is particularly useful for direct application to radial artery access sites, to dialysis graft punctures following de-clotting procedures, to PICC/in-dwelling intravenous lines, and following arterial and venous sheath removal.
- Concentrated PPP obtained as described above can be applied directly in liquid form to the surface of a wound site. The autologous concentrated PPP helps to stop active bleeding from the wound by initiating the body's own clotting mechanisms. If desired, the autologous concentrated PPP may be combined with other presourced procoagulent components such as collagen and thrombin. The autologous concentrated PPP can be used to stop any active surface bleeding, and is particularly considered for direct application to radial artery access sites, to dialysis graft punctures following de-clotting procedures, to PICC/in-dwelling intravenous lines, and following arterial and venous sheath removal.
- In some embodiments, the concentrated fluid of the invention is a combination of PRP and PPP. The concentrated fluid can be autologous. In an embodiment, a concentrator of the invention is used to obtain concentrated platelet rich and concentrated platelet poor plasma from a sample of patient blood during surgery. Whole blood is withdrawn from the patient, and centrifuged in the '142 concentrator for 5 to 30 minutes at 25 to 10000 g, and most preferably for about 15 minutes at 4000 g. The central layers of platelet rich plasma and platelet poor plasma of the centrifuged blood are visually identified by color and withdrawn from the centrifuge chamber. Both layers are simultaneously passed through the filter unit under syringe pressure for one to ten passes, and most preferably 6 passes. The filtration can be tangential flow or dead end. In an embodiment, tangential flow filtration using hollow polysulfone filter fiber membranes with a size cutoff of 0.1 nm to 100,000 nm and a surface area of 1 cm squared to 6000 cm squared is utilized. The filtration results in concentrated platelet rich/platelet poor plasma (“PRP+PPP”). The concentrated PRP+PPP obtained is a viscous liquid having increased concentrations of platelets, white blood cells, fibrinogen, thrombin, clotting factors and associated proteins and structures as compared to whole blood. Various known diluents, such as buffered saline, can be used to adjust the viscosity of the autologous concentrated PRP+PPP for various applications.
- The resultant concentrated PRP+PPP product can be applied during surgery directly to a bone which has been fractured or damaged. The concentrated PRP+PPP produces benefits both of reduced bleeding at the fracture site followed by increased bone growth rates.
- In some embodiments, the concentrated PRP+PPP is mixed with a bone void fillers, such as demineralized bone matrix (“DBM”). Once mixed with the bone void filler, the resultant mixture is applied during surgery in any of numerous applications, including but not limited to spinal fusion, spinal defects, trauma, bone cysts, bone tumors, fracture management, filling of osseous defects, augmenting total joints, sinus augmentation, ridge preservation, joint revisions, posterolateral fusion procedures and general orthopedics applications. Mixing the patient's own concentrated PRP+PPP with bone void filler for surgical application back into the patient results in reduced bleeding followed by increased osteoconductivity and faster bone growth.
- In some embodiments, the concentrated PRP+PPP is applied as a cartilaginous repair material directly to a cartilage defect. If desired, the concentrated PRP+PPP can be mixed with chondrocytes obtained from a different source. In an embodiment, the chondrocytes are isolated by sequential enzymatic digestion of full-thickness articular cartilage of skeletally mature bovines with pronase and collagenase.
- In some embodiments, the concentrated PRP+PPP is applied to an organ or tissue during transplanting, resulting in reduced bleeding followed by better acceptance of the new organ or tissue from the recipient's immune system and a lower chance of rejection.
- In some embodiments, concentrated PRP+PPP is used as a surgical glue material. Either by itself or mixed with other surgical glue materials, the resultant concentrated PRP+PPP is used similar to surgical glue to adhere two tissue portions together.
- The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Those skilled in the art will readily recognize various modifications and changes that may be made to the present invention without following the example embodiments and applications illustrated and described herein, and without departing from the true spirit and scope of the present invention without following the example embodiments and applications illustrated and described herein, and without departing from the true spirit and scope of the present invention, which is set forth in the following claims.
Claims (75)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/666,131 US20100260815A1 (en) | 2007-06-22 | 2008-06-20 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94573307P | 2007-06-22 | 2007-06-22 | |
US12/666,131 US20100260815A1 (en) | 2007-06-22 | 2008-06-20 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
PCT/US2008/067677 WO2009002849A2 (en) | 2007-06-22 | 2008-06-20 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/067677 A-371-Of-International WO2009002849A2 (en) | 2007-06-22 | 2008-06-20 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/322,735 Continuation US10086128B2 (en) | 2007-06-22 | 2014-07-02 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100260815A1 true US20100260815A1 (en) | 2010-10-14 |
Family
ID=39870397
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/666,131 Abandoned US20100260815A1 (en) | 2007-06-22 | 2008-06-20 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
US14/322,735 Active US10086128B2 (en) | 2007-06-22 | 2014-07-02 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/322,735 Active US10086128B2 (en) | 2007-06-22 | 2014-07-02 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US20100260815A1 (en) |
EP (1) | EP2164541A2 (en) |
JP (2) | JP2010531142A (en) |
CN (1) | CN101801431B (en) |
HK (1) | HK1145999A1 (en) |
WO (1) | WO2009002849A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080213872A1 (en) * | 2007-03-02 | 2008-09-04 | John Frederick Regan | Disposable and Removable Nucleic Acid Extraction and Purification Cartridges For Automated Flow-Through Systems |
US20100086529A1 (en) * | 2008-10-08 | 2010-04-08 | Mohammad Syed F | Methods of making concentrated fibrinogen- and platelet-containing compositions |
US8146446B1 (en) * | 2009-03-10 | 2012-04-03 | The United States Of America, As Represented By The Secretary Of The Army | Concentrator device and method of concentrating a liquid sample |
WO2012122227A2 (en) * | 2011-03-07 | 2012-09-13 | Circle Biologics, Inc. | Fluid concentrator with removable cartridge |
US20130048579A1 (en) * | 2011-08-30 | 2013-02-28 | Lawrence Livermore National Security, Llc | Ceramic Filter with Nanofibers |
US20140074011A1 (en) * | 2012-09-13 | 2014-03-13 | Alcon Research, Ltd. | Systems and methods for reinjection of processed vitreous humor |
US20140102968A1 (en) * | 2009-10-09 | 2014-04-17 | John James McEncroe | Pure-Sip |
EP2863221A3 (en) * | 2013-10-15 | 2015-08-26 | Hong Kim | Device and method of extracting high-concentration plasma from whole blood |
WO2017023419A1 (en) | 2015-08-05 | 2017-02-09 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
WO2017096228A1 (en) * | 2015-12-04 | 2017-06-08 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
US20170157374A1 (en) * | 2006-10-09 | 2017-06-08 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
US20180037866A1 (en) * | 2007-03-30 | 2018-02-08 | Smith & Nephew, Inc. | Method of Tissue Harvesting |
US9895518B2 (en) | 2006-10-09 | 2018-02-20 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
WO2020256628A1 (en) * | 2019-06-20 | 2020-12-24 | Amniotics Ab | An apparatus for filtering amniotic fluid |
US11085023B2 (en) | 2015-11-16 | 2021-08-10 | Kenichi Yamahara | Bovine serum composition and method for culturing cells using said bovine serum composition as additive |
US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8961787B2 (en) | 2008-12-01 | 2015-02-24 | General Electric Company | Systems and methods for processing complex biological materials |
KR101720808B1 (en) * | 2008-12-01 | 2017-03-28 | 제너럴 일렉트릭 캄파니 | System and method for separating cells from body fluids |
KR101702154B1 (en) | 2009-03-24 | 2017-02-03 | 유니버시티 오브 시카고 | Device for carrying out a reaction |
US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
US9555171B2 (en) | 2010-09-30 | 2017-01-31 | Depuy Mitek, Llc | Methods and devices for collecting separate components of whole blood |
US8870733B2 (en) * | 2010-11-19 | 2014-10-28 | Kensey Nash Corporation | Centrifuge |
EP2529770A1 (en) | 2011-05-31 | 2012-12-05 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | A digestion system |
EP3578663A1 (en) | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
EP3578652B1 (en) | 2013-03-15 | 2023-07-12 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014165498A1 (en) | 2013-04-02 | 2014-10-09 | Alliance Partners Llc | Fluids concentration cup assembly with hourglass shape |
JP5946866B2 (en) * | 2014-05-09 | 2016-07-06 | キム ホンKim Hong | Highly concentrated plasma extractor |
CN104479995B (en) * | 2014-12-30 | 2016-08-24 | 广州康洛信生物科技有限公司 | Corii Caprae seu Ovis collagen protein extraction system and extracting method |
CZ201552A3 (en) * | 2015-01-28 | 2016-09-29 | Masarykova Univerzita | Use of inorganic nanofibers for capture of compositions with phosphate group in their structure |
US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
WO2016198835A1 (en) | 2015-06-08 | 2016-12-15 | Arquer Diagnostics Limited | Methods and kits |
EP3448564B1 (en) * | 2016-04-29 | 2021-06-09 | Creoptix AG | Methods and assemblies for molecule recovery |
US20200318098A1 (en) * | 2016-06-24 | 2020-10-08 | Modernatx, Inc. | Methods and apparatus for filtration |
WO2018053217A1 (en) | 2016-09-16 | 2018-03-22 | Fenwal, Inc. | Blood separation systems and methods employing centrifugal and spinning membrane separation techniques |
CA3069980A1 (en) * | 2017-07-24 | 2019-01-31 | Arteriocyte Medical Systems, Inc. | Methods of preparing liquid exchanged biological fractions, and devices for use in practicing the same |
CN108169429A (en) * | 2018-01-04 | 2018-06-15 | 邱自文 | Non-newtonian fluid component quick metering device |
KR101930290B1 (en) * | 2018-01-12 | 2018-12-18 | (주)레보메드 | Device for Separating the Body Fluid |
FR3081321B1 (en) * | 2018-05-24 | 2020-06-12 | Imv Technologies | ANIMAL SEED COLLECTION DEVICE |
FR3081292B1 (en) * | 2018-05-24 | 2020-06-05 | Imv Technologies | ANIMAL SEED COLLECTION DEVICE |
EP3705146A3 (en) | 2019-03-05 | 2020-11-25 | Fenwal, Inc. | Collection of mononuclear cells and peripheral blood stem cells |
US11484891B2 (en) | 2019-05-23 | 2022-11-01 | Fenwal, Inc. | Adjustment of target interface location between separated fluid components in a centrifuge |
EP4238596A3 (en) | 2019-05-23 | 2023-12-13 | Fenwal, Inc. | Centrifugal separation and collection of red blood cells or both red blood cells and plasma |
CN112495596B (en) | 2019-09-16 | 2022-07-26 | 汾沃有限公司 | Dynamic adjustment of algorithms for separation and collection of blood components |
WO2021216177A1 (en) * | 2020-04-23 | 2021-10-28 | Hanuman Pelican, Inc. | Plasma/cell concentrator apparatus and methods |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3669789A (en) * | 1969-03-22 | 1972-06-13 | Fuji Photo Film Co Ltd | Method of making plastic fiber-optical plates |
US4230564A (en) * | 1978-07-24 | 1980-10-28 | Keefer Bowie | Rotary reverse osmosis apparatus and method |
US4327177A (en) * | 1969-04-10 | 1982-04-27 | Wallace Shrimpton | Method and means for controlling the sex of mammalian offspring and product therefor |
US4886597A (en) * | 1987-09-24 | 1989-12-12 | Her Majesty The Queen In Right Of Canada | Centrifugal reverse-osmosis desalination unit |
US5165938A (en) * | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5891347A (en) * | 1996-01-17 | 1999-04-06 | Matsumoto Machine Mfg. Co., Ltd. | Centrifugal filtration method and apparatus therefor |
US6010627A (en) * | 1995-06-06 | 2000-01-04 | Quantic Biomedical Partners | Device for concentrating plasma |
US6027655A (en) * | 1993-11-19 | 2000-02-22 | Bristol-Myers Squibb Company | Apparatus and method for centrifugally separating blood and then forming a fibrin monomer |
US6063297A (en) * | 1994-12-07 | 2000-05-16 | Plasmaseal Llc | Method and apparatus for making concentrated plasma and/or tissue sealant |
US6106727A (en) * | 1992-07-13 | 2000-08-22 | Pall Corporation | Automated system and method for processing biological fluid |
US6132613A (en) * | 1996-06-04 | 2000-10-17 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Centrifugal reverse-osmosis desalination unit incorporating an annular membrane cartridge |
US6524568B2 (en) * | 1998-06-22 | 2003-02-25 | Cytomedix, Inc. | Enriched platelet wound healant |
US20040132003A1 (en) * | 1996-04-30 | 2004-07-08 | Dolecek Victor D. | Method for the production of a blood component composition |
US20040182795A1 (en) * | 2003-03-21 | 2004-09-23 | Randel Dorian | Apparatus and method for concentration of plasma from whole blood |
US20050095695A1 (en) * | 2003-11-05 | 2005-05-05 | Shindler Melvin S. | Nanofibrillar structure and applications including cell and tissue culture |
US20050184012A1 (en) * | 2004-02-23 | 2005-08-25 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US20060060521A1 (en) * | 2002-12-19 | 2006-03-23 | Utisol Technologies Ag | Filter device |
US7077273B2 (en) * | 2000-04-28 | 2006-07-18 | Harvest Technologies Corporation | Blood component separator disk |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3894529A (en) * | 1969-04-10 | 1975-07-15 | Bio Controls Inc | Method and means for controlling the sex of mammalian offspring and product therefor |
US5167812A (en) * | 1984-11-28 | 1992-12-01 | Trustees Of The Univ. Of Penna. | Affinity chromatogry using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed |
JPH0747303A (en) * | 1993-06-01 | 1995-02-21 | Asahi Medical Co Ltd | Centrifugal separation device and centrifugal separation method for blood bag unit with filter for removing leukocyte |
JPH1014565A (en) * | 1996-07-01 | 1998-01-20 | Asahi Medical Co Ltd | Hematopoietic stem cell concentrating material, hematopoietic stem cell concentrating filter and concentration of hematopoietic stem cell |
EP1057534A1 (en) * | 1999-06-03 | 2000-12-06 | Haemonetics Corporation | Centrifugation bowl with filter core |
JP2002045170A (en) * | 2000-07-31 | 2002-02-12 | Toshiba Ceramics Co Ltd | Apparatus and method for concentrating microorganism |
RU2304463C2 (en) * | 2001-06-22 | 2007-08-20 | Аргонид Корпорейшн | One-nanometer positive fiber adsorbent |
DE10138564B4 (en) * | 2001-08-06 | 2007-07-12 | Lamm, Peter Wilhelm, Dr. | Method of devitalizing natural organs and / or providing extracellular matrices for tissue engineering |
US7585670B2 (en) * | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US7291450B2 (en) * | 2003-03-28 | 2007-11-06 | Smith & Nephew, Inc. | Preparation of a cell concentrate from a physiological solution |
US7790039B2 (en) * | 2003-11-24 | 2010-09-07 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for stem cell enrichment |
-
2008
- 2008-06-20 JP JP2010513448A patent/JP2010531142A/en active Pending
- 2008-06-20 EP EP08771598A patent/EP2164541A2/en not_active Withdrawn
- 2008-06-20 CN CN200880101718.2A patent/CN101801431B/en active Active
- 2008-06-20 WO PCT/US2008/067677 patent/WO2009002849A2/en active Application Filing
- 2008-06-20 US US12/666,131 patent/US20100260815A1/en not_active Abandoned
-
2011
- 2011-01-13 HK HK11100326.2A patent/HK1145999A1/en unknown
-
2013
- 2013-12-26 JP JP2013270089A patent/JP2014128268A/en active Pending
-
2014
- 2014-07-02 US US14/322,735 patent/US10086128B2/en active Active
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3669789A (en) * | 1969-03-22 | 1972-06-13 | Fuji Photo Film Co Ltd | Method of making plastic fiber-optical plates |
US4327177A (en) * | 1969-04-10 | 1982-04-27 | Wallace Shrimpton | Method and means for controlling the sex of mammalian offspring and product therefor |
US4230564A (en) * | 1978-07-24 | 1980-10-28 | Keefer Bowie | Rotary reverse osmosis apparatus and method |
US5165938A (en) * | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
US4886597A (en) * | 1987-09-24 | 1989-12-12 | Her Majesty The Queen In Right Of Canada | Centrifugal reverse-osmosis desalination unit |
US6106727A (en) * | 1992-07-13 | 2000-08-22 | Pall Corporation | Automated system and method for processing biological fluid |
US6027655A (en) * | 1993-11-19 | 2000-02-22 | Bristol-Myers Squibb Company | Apparatus and method for centrifugally separating blood and then forming a fibrin monomer |
US6063297A (en) * | 1994-12-07 | 2000-05-16 | Plasmaseal Llc | Method and apparatus for making concentrated plasma and/or tissue sealant |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US6010627A (en) * | 1995-06-06 | 2000-01-04 | Quantic Biomedical Partners | Device for concentrating plasma |
US6342157B1 (en) * | 1995-06-06 | 2002-01-29 | Interpore Orthopedics, Inc. | Device and method for concentrating plasma |
US5891347A (en) * | 1996-01-17 | 1999-04-06 | Matsumoto Machine Mfg. Co., Ltd. | Centrifugal filtration method and apparatus therefor |
US20040132003A1 (en) * | 1996-04-30 | 2004-07-08 | Dolecek Victor D. | Method for the production of a blood component composition |
US6132613A (en) * | 1996-06-04 | 2000-10-17 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Centrifugal reverse-osmosis desalination unit incorporating an annular membrane cartridge |
US6524568B2 (en) * | 1998-06-22 | 2003-02-25 | Cytomedix, Inc. | Enriched platelet wound healant |
US7547272B2 (en) * | 2000-04-28 | 2009-06-16 | Harvest Technologies Corporation | Blood components separator disk |
US7077273B2 (en) * | 2000-04-28 | 2006-07-18 | Harvest Technologies Corporation | Blood component separator disk |
US20060060521A1 (en) * | 2002-12-19 | 2006-03-23 | Utisol Technologies Ag | Filter device |
US20040182795A1 (en) * | 2003-03-21 | 2004-09-23 | Randel Dorian | Apparatus and method for concentration of plasma from whole blood |
US20050095695A1 (en) * | 2003-11-05 | 2005-05-05 | Shindler Melvin S. | Nanofibrillar structure and applications including cell and tissue culture |
US20050184012A1 (en) * | 2004-02-23 | 2005-08-25 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US7740760B2 (en) * | 2004-02-23 | 2010-06-22 | Circle Biologics, Llc. | Fluid concentrator |
US7803279B2 (en) * | 2004-02-23 | 2010-09-28 | Circle Biologics, Llc. | Method of concentrating a component from a fluid |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10695545B2 (en) * | 2006-10-09 | 2020-06-30 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
US20170157374A1 (en) * | 2006-10-09 | 2017-06-08 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
US9895518B2 (en) | 2006-10-09 | 2018-02-20 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US11529452B2 (en) | 2006-10-09 | 2022-12-20 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US11065425B2 (en) | 2006-10-09 | 2021-07-20 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
US10398884B2 (en) | 2006-10-09 | 2019-09-03 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US20200046954A1 (en) | 2006-10-09 | 2020-02-13 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US8828716B2 (en) * | 2007-03-02 | 2014-09-09 | Lawrence Livermore National Security LLC. | Disposable and removable nucleic acid extraction and purification cartridges for automated flow-through systems |
US20080213872A1 (en) * | 2007-03-02 | 2008-09-04 | John Frederick Regan | Disposable and Removable Nucleic Acid Extraction and Purification Cartridges For Automated Flow-Through Systems |
US20180037866A1 (en) * | 2007-03-30 | 2018-02-08 | Smith & Nephew, Inc. | Method of Tissue Harvesting |
US20100086529A1 (en) * | 2008-10-08 | 2010-04-08 | Mohammad Syed F | Methods of making concentrated fibrinogen- and platelet-containing compositions |
US8146446B1 (en) * | 2009-03-10 | 2012-04-03 | The United States Of America, As Represented By The Secretary Of The Army | Concentrator device and method of concentrating a liquid sample |
US20140102968A1 (en) * | 2009-10-09 | 2014-04-17 | John James McEncroe | Pure-Sip |
WO2012122227A2 (en) * | 2011-03-07 | 2012-09-13 | Circle Biologics, Inc. | Fluid concentrator with removable cartridge |
US9011684B2 (en) | 2011-03-07 | 2015-04-21 | Spinesmith Holdings, Llc | Fluid concentrator with removable cartridge |
WO2012122227A3 (en) * | 2011-03-07 | 2012-11-15 | Circle Biologics, Inc. | Fluid concentrator with removable cartridge |
US20130048579A1 (en) * | 2011-08-30 | 2013-02-28 | Lawrence Livermore National Security, Llc | Ceramic Filter with Nanofibers |
US9549849B2 (en) * | 2012-09-13 | 2017-01-24 | Alcon Research, Ltd. | Systems and methods for reinjection of processed vitreous humor |
EP2882389A4 (en) * | 2012-09-13 | 2016-04-27 | Alcon Res Ltd | Reinjection of processed vitreous humor |
WO2014042832A1 (en) | 2012-09-13 | 2014-03-20 | Alcon Research, Ltd. | Reinjection of processed vitreous humor |
US20140074011A1 (en) * | 2012-09-13 | 2014-03-13 | Alcon Research, Ltd. | Systems and methods for reinjection of processed vitreous humor |
EP2863221A3 (en) * | 2013-10-15 | 2015-08-26 | Hong Kim | Device and method of extracting high-concentration plasma from whole blood |
US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
EP3331586A4 (en) * | 2015-08-05 | 2019-04-03 | Minnetronix Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
AU2019283901B2 (en) * | 2015-08-05 | 2021-05-20 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
EP3714915A1 (en) * | 2015-08-05 | 2020-09-30 | Minnetronix Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
WO2017023419A1 (en) | 2015-08-05 | 2017-02-09 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US11085023B2 (en) | 2015-11-16 | 2021-08-10 | Kenichi Yamahara | Bovine serum composition and method for culturing cells using said bovine serum composition as additive |
EP3842080A1 (en) * | 2015-12-04 | 2021-06-30 | Minnetronix Inc. | Systems for the conditioning of cerebrospinal fluid |
WO2017096228A1 (en) * | 2015-12-04 | 2017-06-08 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
US11577060B2 (en) | 2015-12-04 | 2023-02-14 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
WO2020256628A1 (en) * | 2019-06-20 | 2020-12-24 | Amniotics Ab | An apparatus for filtering amniotic fluid |
Also Published As
Publication number | Publication date |
---|---|
WO2009002849A2 (en) | 2008-12-31 |
US20150157781A1 (en) | 2015-06-11 |
JP2010531142A (en) | 2010-09-24 |
HK1145999A1 (en) | 2011-05-13 |
EP2164541A2 (en) | 2010-03-24 |
JP2014128268A (en) | 2014-07-10 |
WO2009002849A3 (en) | 2009-03-19 |
CN101801431A (en) | 2010-08-11 |
CN101801431B (en) | 2014-11-19 |
US10086128B2 (en) | 2018-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10086128B2 (en) | Fluid concentrator, autologous concentrated body fluids, and uses thereof | |
AU2005229049B2 (en) | Preparation of a nucleated cell and/or platelet concentrate from a physiological solution | |
US10272139B2 (en) | Process, tube and device for the preparation of wound healant composition | |
KR20060136475A (en) | Preparation of a nucleated cell and/or platelet concentrate from a physiological solution | |
US20060128016A1 (en) | Fibrin-containing composition | |
US11419961B2 (en) | Bone induction system and methods | |
JP2012006937A (en) | Method and device for separating liquid component | |
US10639333B2 (en) | Process for removing growth factors from platelets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MILLENNIUM MEDICAL TECHNOLOGIES, INC., NEW MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KYLE, MATTHEW R.;COULL, ELIZABETH S.;SIGNING DATES FROM 20090826 TO 20090909;REEL/FRAME:023213/0507 Owner name: CIRCLE BIOLOGICS, LLC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLENNIUM MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:023208/0386 Effective date: 20090909 |
|
AS | Assignment |
Owner name: MILLENNIUM MEDICAL TECHNOLOGIES, INC., NEW MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KYLE, MATTHEW R.;COULL, THOMAS;SIGNING DATES FROM 20090826 TO 20090909;REEL/FRAME:023696/0386 Owner name: CIRCLE BIOLOGICS, LLC, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLENNIUM MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:023696/0412 Effective date: 20090909 |
|
AS | Assignment |
Owner name: CIRCLE BIOLOGICS, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CIRCLE BIOLOGICS, LLC;REEL/FRAME:026665/0944 Effective date: 20110725 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |